Merck & Co.(NYSE:MRK) 
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiov...
Website: http://www.merck.com
Founded: 1891
Full Time Employees: 71,000
Sector: Healthcare
Industry: Drug Manufacturers-General
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
- Keytruda Remains the Primary Growth Engine: Merck’s oncology franchise continues to be anchored by Keytruda, which is central to revenue growth and ongoing label expansion efforts across tumor types and treatment settings.
- Patent Expiry Risk Creates a Looming Revenue Cliff: Upcoming loss of exclusivity—especially for Keytruda later this decade—raises medium-term risk, increasing the importance of lifecycle management, new launches, and pipeline execution.
- Pipeline and Business Development Are Critical to Diversification: Merck is investing heavily in internal R&D and acquisitions/partnerships to broaden its portfolio beyond oncology and mitigate concentration risk tied to a small number of blockbuster products.
- Animal Health Provides a Steady, Diversifying Earnings Stream: The Animal Health segment typically contributes resilient demand and cash generation, helping balance cyclicality and patent-cycle risk within the human pharmaceuticals business.
- Strong Cash Flow Supports Shareholder Returns and Investment: Merck’s scale and profitability generally enable continued dividends and capital return while funding R&D and targeted dealmaking, though large acquisitions can shift near-term leverage and capital allocation priorities.
Bull Thesis:
- Keytruda's Enduring Dominance and Pipeline Expansion: Keytruda (pembrolizumab) continues to be a blockbuster drug with expanding indications across various cancer types, driving significant revenue growth. Merck's robust R&D pipeline, particularly in oncology, vaccines, and cardiovascular, aims to discover and develop the next generation of market-leading therapies, ensuring long-term growth beyond Keytruda's eventual patent expiry.
- Strong Vaccine Portfolio Performance: Merck's vaccine division, led by Gardasil (HPV vaccine) and Vaxneuvance (pneumococcal vaccine), provides a stable and high-margin revenue stream. Global demand for preventative health solutions, especially in emerging markets, continues to drive growth for these essential products, diversifying Merck's revenue base.
- Healthy Financial Position and Shareholder Returns: Merck maintains a strong balance sheet, generates substantial free cash flow, and consistently returns capital to shareholders through a reliable dividend and share repurchase programs. This financial strength provides flexibility for strategic investments, M&A opportunities, and resilience against market fluctuations.
- Strategic Focus on High-Growth Therapeutic Areas: Through strategic divestitures (e.g., Organon spin-off), Merck has sharpened its focus on high-growth, high-margin therapeutic areas such as oncology, vaccines, and hospital acute care. This streamlined portfolio allows for more concentrated R&D investment and commercial efforts in areas with significant unmet medical needs and market potential.
Bear Thesis:
- Keytruda Patent Cliff Risk: While still several years away (late 2020s), the eventual patent expiration of Keytruda poses a significant long-term revenue challenge. The company's ability to successfully launch new blockbuster drugs from its pipeline to offset this revenue decline is critical and carries inherent R&D and commercialization risks.
- R&D Productivity and Pipeline Execution Uncertainty: Despite substantial R&D investment, the pharmaceutical industry faces high attrition rates in clinical development. Failure to successfully bring new, innovative drugs to market or to achieve expected commercial success for pipeline assets could significantly impact future growth prospects and investor confidence.
- Increasing Competition and Biosimilar Threats: The pharmaceutical market is highly competitive, with new entrants and existing players constantly developing alternative therapies. Additionally, the rise of biosimilars for older, established drugs could erode market share and pricing power for some of Merck's non-Keytruda products, impacting overall profitability.
- Regulatory and Pricing Pressures: Governments and payers globally are intensifying scrutiny on drug pricing, leading to potential legislative actions (e.g., Inflation Reduction Act in the U.S.) and increased pressure for price concessions. These pressures could negatively impact Merck's revenue growth and profit margins, particularly for its high-value drugs.
Main Competitors:
- Pfizer Inc. ($PFE) (Oncology (e.g., Ibrance), Vaccines (e.g., Prevnar), Internal Medicine), Pfizer competes with Merck across a wide range of therapeutic areas, including oncology, where its drugs like Ibrance compete in certain cancer types, and in vaccines, where its Prevnar franchise is a direct competitor to Merck's pneumococcal vaccines. Pfizer leverages its extensive R&D capabilities and global commercial footprint to challenge Merck in various markets.
- Bristol Myers Squibb (BMS) ($BMY) (Immuno-Oncology (e.g., Opdivo), Hematology, Immunology), BMS is a major competitor in the high-growth immuno-oncology space, with its drug Opdivo directly competing with Merck's Keytruda for market share across numerous cancer indications. They also compete in other specialty areas like hematology and immunology, driven by a strong pipeline and focus on innovative therapies.
- Johnson & Johnson (Janssen Pharmaceutical Companies) ($JNJ) (Oncology (e.g., Darzalex, Erleada), Immunology (e.g., Stelara), Neuroscience), Johnson & Johnson's pharmaceutical division, Janssen, competes with Merck across multiple therapeutic areas. In oncology, Janssen's drugs like Darzalex and Erleada challenge Merck's portfolio. They also have strong positions in immunology and neuroscience, backed by a diverse pipeline and global presence, making them a broad-based pharmaceutical rival.
- AstraZeneca PLC ($AZN) (Oncology (e.g., Tagrisso, Imfinzi, Lynparza), Cardiovascular, Renal & Metabolism, Respiratory), AstraZeneca is a significant competitor, particularly in oncology, with a robust portfolio including Tagrisso, Imfinzi, and Lynparza, which target various cancer types and mechanisms, often overlapping with Merck's oncology focus. They also compete in other key therapeutic areas like cardiovascular, renal & metabolism, and respiratory diseases.
- Roche Holding AG ($RHHBY) (Oncology (e.g., Tecentriq, Herceptin, Avastin), Immunology, Diagnostics), Roche is a global leader in oncology and diagnostics, competing with Merck through its strong portfolio of cancer treatments such as Tecentriq (another immuno-oncology drug), Herceptin, and Avastin. Roche's integrated approach, combining pharmaceuticals with diagnostics, provides a unique competitive edge in personalized healthcare.
Moat:
Merck's competitive moat is primarily built upon its robust R&D engine, leading to a strong pipeline of innovative drugs, most notably its blockbuster immuno-oncology drug Keytruda, which holds a dominant market position across numerous cancer indications. Its established vaccine portfolio, including Gardasil and pneumococcal vaccines, also provides significant recurring revenue and market leadership. Further strengthening its moat are extensive intellectual property protections and a global commercial infrastructure. However, Merck operates in a highly competitive landscape, facing intense rivalry from other major pharmaceutical companies like Pfizer, Bristol Myers Squibb, Johnson & Johnson, AstraZeneca, and Roche. These competitors vie for market share across key therapeutic areas, particularly oncology and vaccines, through their own R&D efforts and product portfolios. The industry also presents challenges such as patent expirations, the high cost and risk of drug development, and increasing pricing pressure from healthcare systems globally.
Income Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
sales | 16,286,000,000 | 16,400,000,000 | 17,276,000,000 | 15,806,000,000 | 15,529,000,000 | 15,624,000,000 | 16,657,000,000 | 16,112,000,000 | 15,775,000,000 | 14,630,000,000 | 15,962,000,000 | 15,035,000,000 | 14,487,000,000 | 13,830,000,000 | 14,959,000,000 | 14,593,000,000 | 15,901,000,000 | 13,521,000,000 | 13,154,000,000 | 11,402,000,000 | 12,080,000,000 | 12,515,000,000 | 12,551,000,000 | 10,872,000,000 | 12,057,000,000 | 7,322,000,000 | 12,397,000,000 | 11,760,000,000 | 10,816,000,000 | 8,826,000,000 | 10,794,000,000 | 10,465,000,000 | 10,037,000,000 | 10,433,000,000 | 10,325,000,000 | 9,930,000,000 | 9,434,000,000 | 10,115,000,000 | 10,536,000,000 | 9,844,000,000 | 9,312,000,000 | 10,215,000,000 | 10,073,000,000 | 9,785,000,000 | 9,425,000,000 | 10,482,000,000 | 10,557,000,000 | 10,934,000,000 | 10,264,000,000 | 11,320,000,000 | 11,032,000,000 | 11,010,000,000 | 10,671,000,000 | 11,737,000,000 | 11,488,000,000 | 12,311,000,000 | 11,731,000,000 | 12,294,000,000 | 12,022,000,000 | 12,151,000,000 | 11,580,000,000 | 12,093,700,000 | 11,124,900,000 | 11,346,300,000 | 11,422,200,000 | |||||||||
yoy | 4.87% | 4.97% | 3.72% | -1.90% | -1.56% | 6.79% | 4.35% | 7.16% | 8.89% | 5.78% | 6.70% | 3.03% | -8.89% | 2.29% | 13.72% | 27.99% | 31.63% | 8.04% | 4.80% | 4.87% | 0.19% | 70.92% | 1.24% | -7.55% | 11.47% | -17.04% | 14.85% | 12.37% | 7.76% | -15.40% | 4.54% | 5.39% | 6.39% | 3.14% | -2.00% | 0.87% | 1.31% | -0.98% | 4.60% | 0.60% | -1.20% | -2.55% | -4.58% | -10.51% | -8.17% | -7.40% | -4.31% | -0.69% | -3.81% | -3.55% | -3.97% | -10.57% | -9.04% | -4.53% | -4.44% | 1.32% | 1.30% | 1.66% | 8.06% | 7.09% | 1.38% | |||||||||||||
qoq | -0.70% | -5.07% | 9.30% | 1.78% | -0.61% | -6.20% | 3.38% | 2.14% | 7.83% | -8.34% | 6.17% | 3.78% | 4.75% | -7.55% | 2.51% | -8.23% | 17.60% | 2.79% | 15.37% | -5.61% | -3.48% | -0.29% | 15.44% | -9.83% | 64.67% | -40.94% | 5.42% | 8.73% | 22.55% | -18.23% | 3.14% | 4.26% | -3.80% | 1.05% | 3.98% | 5.26% | -6.73% | -4.00% | 7.03% | 5.71% | -8.84% | 1.41% | 2.94% | 3.82% | -10.08% | -0.71% | -3.45% | 6.53% | -9.33% | 2.61% | 0.20% | 3.18% | -9.08% | 2.17% | -6.69% | 4.94% | -4.58% | 2.26% | -1.06% | 4.93% | -4.25% | 8.71% | -1.95% | -0.66% | ||||||||||
costs, expenses and other | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cost of sales | 4,195,000,000 | 5,551,000,000 | 3,855,000,000 | 3,557,000,000 | 3,419,000,000 | 3,828,000,000 | 4,080,000,000 | 3,745,000,000 | 3,540,000,000 | 3,912,000,000 | 4,264,000,000 | 4,024,000,000 | 3,926,000,000 | 3,881,000,000 | 3,934,000,000 | 4,216,000,000 | 5,380,000,000 | 3,874,000,000 | 3,450,000,000 | 3,104,000,000 | 3,670,000,000 | 5,533,000,000 | 3,481,000,000 | 3,159,000,000 | 3,312,000,000 | 2,610,750,000 | 3,990,000,000 | 3,401,000,000 | 3,052,000,000 | 429,750,000 | 1,719,000,000 | 1,620,000,000 | 1,399,000,000 | -1,736,992,693 | 1,737,000,000 | 1,908,000,000 | 2,137,000,000 | |||||||||||||||||||||||||||||||||||||
selling, general and administrative | 2,700,000,000 | 2,898,000,000 | 2,633,000,000 | 2,649,000,000 | 2,552,000,000 | 2,864,000,000 | 2,731,000,000 | 2,739,000,000 | 2,483,000,000 | 2,804,000,000 | 2,519,000,000 | 2,702,000,000 | 2,479,000,000 | 2,687,000,000 | 2,520,000,000 | 2,512,000,000 | 2,323,000,000 | 2,830,000,000 | 2,336,000,000 | 2,281,000,000 | 2,633,000,000 | 3,085,000,000 | 2,450,000,000 | 2,378,000,000 | 2,555,000,000 | 1,931,500,000 | 2,589,000,000 | 2,712,000,000 | 2,425,000,000 | 377,750,000 | 1,511,000,000 | 1,626,000,000 | 1,493,000,000 | -1,659,993,177 | 1,660,000,000 | 1,870,000,000 | 1,676,000,000 | |||||||||||||||||||||||||||||||||||||
research and development | 12,592,000,000 | 3,886,000,000 | 4,234,000,000 | 4,048,000,000 | 3,621,000,000 | 4,584,000,000 | 5,862,000,000 | 3,500,000,000 | 3,992,000,000 | 9,627,000,000 | 3,307,000,000 | 13,321,000,000 | 4,276,000,000 | 3,775,000,000 | 4,399,000,000 | 2,798,000,000 | 2,576,000,000 | 3,068,000,000 | 2,445,000,000 | 4,321,000,000 | 2,465,000,000 | 5,837,000,000 | 3,390,000,000 | 2,123,000,000 | 2,209,000,000 | 1,831,000,000 | 3,204,000,000 | 2,189,000,000 | 1,931,000,000 | 1,884,500,000 | 2,068,000,000 | 2,274,000,000 | 3,196,000,000 | 2,281,000,000 | 4,383,000,000 | 1,749,000,000 | 1,796,000,000 | 4,649,000,000 | 1,664,000,000 | 2,151,000,000 | 1,659,000,000 | 1,798,000,000 | 1,500,000,000 | 1,670,000,000 | 1,737,000,000 | 2,283,000,000 | 1,659,000,000 | 1,664,000,000 | 1,574,000,000 | 1,835,000,000 | 1,660,000,000 | 2,101,000,000 | 1,907,000,000 | 2,224,000,000 | 1,918,000,000 | 2,165,000,000 | 1,862,000,000 | 2,419,000,000 | 1,954,000,000 | 1,936,000,000 | 2,158,000,000 | 1,618,500,000 | 2,296,400,000 | 2,150,900,000 | 2,026,700,000 | 4,932,000,000 | 913,000,000 | 863,000,000 | 804,000,000 | -892,996,471 | 893,000,000 | 906,000,000 | 880,000,000 | |
restructuring costs | 195,000,000 | 213,000,000 | 47,000,000 | 560,000,000 | 69,000,000 | 51,000,000 | 56,000,000 | 80,000,000 | 123,000,000 | 255,000,000 | 126,000,000 | 151,000,000 | 67,000,000 | 49,000,000 | 94,000,000 | 142,000,000 | 53,000,000 | 174,000,000 | 107,000,000 | 82,000,000 | 298,000,000 | 309,000,000 | 114,000,000 | 83,000,000 | 72,000,000 | 111,000,000 | 232,000,000 | 59,000,000 | 153,000,000 | 123,500,000 | 171,000,000 | 228,000,000 | 95,000,000 | 306,000,000 | 153,000,000 | 166,000,000 | 151,000,000 | 265,000,000 | 161,000,000 | 134,000,000 | 91,000,000 | 233,000,000 | 113,000,000 | 191,000,000 | 82,000,000 | 349,000,000 | 376,000,000 | 163,000,000 | 125,000,000 | 565,000,000 | 870,000,000 | 155,000,000 | 119,000,000 | 191,000,000 | 110,000,000 | 144,000,000 | 219,000,000 | 533,000,000 | 119,000,000 | 668,000,000 | -14,000,000 | 121,400,000 | 49,600,000 | 526,300,000 | 287,700,000 | |||||||||
other expense | 138,000,000 | 432,000,000 | -238,000,000 | -7,000,000 | -35,000,000 | 127,000,000 | -162,000,000 | 42,000,000 | -33,000,000 | 78,000,000 | 126,000,000 | 172,000,000 | 89,000,000 | -75,000,000 | 429,000,000 | 438,000,000 | 708,000,000 | -334,000,000 | -450,000,000 | -103,000,000 | -448,000,000 | -256,000,000 | -312,000,000 | -390,000,000 | 71,000,000 | 90,500,000 | 35,000,000 | 140,000,000 | 188,000,000 | -128,000,000 | -172,000,000 | -48,000,000 | -291,000,000 | -18,000,000 | -86,000,000 | 58,000,000 | 58,000,000 | 632,000,000 | 22,000,000 | 19,000,000 | 903,000,000 | -170,000,000 | 739,000,000 | 55,000,000 | -184,250,000 | -142,000,000 | -558,000,000 | -39,000,000 | 159,000,000 | 172,000,000 | 201,000,000 | 282,000,000 | 670,000,000 | 200,000,000 | 103,000,000 | 142,000,000 | ||||||||||||||||||
costs, expenses and other - sum | 19,820,000,000 | 12,980,000,000 | 10,531,000,000 | 10,807,000,000 | 9,626,000,000 | 11,454,000,000 | 12,567,000,000 | 10,106,000,000 | 10,105,000,000 | 16,676,000,000 | 10,342,000,000 | 20,370,000,000 | 10,837,000,000 | 10,317,000,000 | 11,376,000,000 | 10,106,000,000 | 11,040,000,000 | 9,612,000,000 | 7,888,000,000 | 9,685,000,000 | 8,618,000,000 | 14,508,000,000 | 9,123,000,000 | 7,353,000,000 | 8,219,000,000 | 6,574,750,000 | 10,050,000,000 | 8,501,000,000 | 7,749,000,000 | 6,299,750,000 | 8,129,000,000 | 8,379,000,000 | 8,692,000,000 | 8,554,000,000 | 10,125,000,000 | 7,491,000,000 | 7,431,000,000 | 11,471,000,000 | 7,649,000,000 | 8,340,000,000 | 9,399,000,000 | 7,676,000,000 | 8,978,000,000 | 8,044,000,000 | 6,570,750,000 | 9,067,000,000 | 9,043,000,000 | 8,173,000,000 | 10,095,000,000 | 9,507,000,000 | 9,765,000,000 | 9,121,000,000 | 10,403,000,000 | 9,270,000,000 | 9,631,000,000 | 9,224,000,000 | ||||||||||||||||||
income before taxes | -3,534,000,000 | 3,420,000,000 | 6,745,000,000 | 4,999,000,000 | 5,903,000,000 | 4,170,000,000 | 4,090,000,000 | 6,006,000,000 | 5,670,000,000 | 983,750,000 | 5,620,000,000 | -5,335,000,000 | 3,650,000,000 | 3,462,000,000 | -1,993,000,000 | 3,428,000,000 | 3,519,000,000 | 3,838,000,000 | 2,168,250,000 | 2,347,000,000 | 3,259,000,000 | 3,067,000,000 | 1,524,250,000 | 2,665,000,000 | 2,086,000,000 | 1,345,000,000 | 1,879,000,000 | 200,000,000 | 2,439,000,000 | 2,003,000,000 | -1,356,000,000 | 2,887,000,000 | 1,504,000,000 | 1,624,000,000 | 816,000,000 | 2,397,000,000 | 807,000,000 | 1,381,000,000 | 11,811,000,000 | 1,490,000,000 | 1,891,000,000 | 2,091,000,000 | 1,225,000,000 | 1,525,000,000 | 1,245,000,000 | 1,550,000,000 | 1,334,000,000 | 2,218,000,000 | 2,680,000,000 | 2,507,000,000 | 1,581,000,000 | 2,352,000,000 | 1,672,000,000 | 1,729,000,000 | -701,200,000 | 497,700,000 | 1,240,800,000 | 615,800,000 | ||||||||||||||||
income tax provision | 709,000,000 | 545,000,000 | 637,000,000 | 277,000,000 | 566,000,000 | 119,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | -4,243,000,000 | 2,962,000,000 | 5,787,000,000 | 4,428,000,000 | 5,085,000,000 | 3,744,000,000 | 3,161,000,000 | 5,461,000,000 | 4,767,000,000 | -1,602,860,000 | 4,750,000,000 | -5,972,000,000 | 2,825,000,000 | 1,180,000 | 1,280,000 | 1,560,000 | 1,700,000 | 1,490,000 | 1,810,000 | 610,000 | 3,186,000,000 | -2,091,000,000 | 2,945,000,000 | 3,010,000,000 | 3,219,000,000 | 1,853,500,000 | 1,907,000,000 | 2,644,000,000 | 2,862,000,000 | 1,103,750,000 | 1,958,000,000 | 1,716,000,000 | 741,000,000 | -1,038,000,000 | -51,000,000 | 1,951,000,000 | 1,556,000,000 | -587,000,000 | 2,188,000,000 | 1,209,000,000 | 1,130,000,000 | 982,000,000 | 1,831,000,000 | 688,000,000 | 958,000,000 | 7,327,000,000 | 842,000,000 | 2,033,000,000 | 1,731,000,000 | 815,000,000 | 1,150,000,000 | 935,000,000 | 1,616,000,000 | 949,000,000 | 1,763,000,000 | 1,820,000,000 | 1,767,000,000 | 1,543,000,000 | 1,724,000,000 | 2,054,000,000 | 1,071,000,000 | -500,000,000 | 371,700,000 | 780,200,000 | 330,200,000 | 12,509,200,000 | 515,000,000 | 671,000,000 | 805,000,000 | 147,250,000 | 589,000,000 | 436,000,000 | 291,000,000 | |
less: net income attributable to noncontrolling interests | -3,000,000 | -1,000,000 | 2,000,000 | 1,000,000 | 6,000,000 | 1,000,000 | 4,000,000 | 6,000,000 | 5,000,000 | 5,000,000 | 3,000,000 | 4,000,000 | 1,000,000 | 5,000,000 | 5,000,000 | -3,000,000 | 4,000,000 | 4,000,000 | 1,000,000 | 7,000,000 | 3,000,000 | 4,000,000 | 8,000,000 | -18,250,000 | 6,000,000 | -26,000,000 | -53,000,000 | 5,500,000 | 8,000,000 | 9,000,000 | 5,000,000 | 8,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 8,000,000 | 4,000,000 | 4,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 1,000,000 | 5,000,000 | 11,000,000 | -53,000,000 | 29,000,000 | 26,000,000 | 34,000,000 | 26,000,000 | 29,000,000 | 23,000,000 | 42,000,000 | 34,000,000 | 27,000,000 | 29,000,000 | 31,000,000 | 32,000,000 | 30,000,000 | 28,000,000 | 22,325,000 | 30,100,000 | 27,800,000 | 31,400,000 | |||||||||||
net income attributable to merck & co., inc. | -4,240,000,000 | 2,963,000,000 | 5,785,000,000 | 4,427,000,000 | 5,079,000,000 | 3,743,000,000 | 3,157,000,000 | 5,455,000,000 | 4,762,000,000 | -1,226,000,000 | 4,745,000,000 | -5,975,000,000 | 2,821,000,000 | 3,017,000,000 | 3,248,000,000 | 3,944,000,000 | 4,310,000,000 | 3,758,000,000 | 4,567,000,000 | 1,545,000,000 | 3,179,000,000 | -2,094,000,000 | 2,941,000,000 | 3,002,000,000 | 3,219,000,000 | 1,871,750,000 | 1,901,000,000 | 2,670,000,000 | 2,915,000,000 | 1,098,250,000 | 1,950,000,000 | 1,707,000,000 | 736,000,000 | -1,046,000,000 | -56,000,000 | 1,946,000,000 | 1,551,000,000 | -595,000,000 | 2,184,000,000 | 1,205,000,000 | 1,125,000,000 | 977,000,000 | 1,826,000,000 | 687,000,000 | 953,000,000 | 7,316,000,000 | 895,000,000 | 2,004,000,000 | 1,705,000,000 | 781,000,000 | 1,124,000,000 | 906,000,000 | 1,593,000,000 | 907,000,000 | 1,729,000,000 | 1,793,000,000 | 1,738,000,000 | 1,512,000,000 | 1,692,000,000 | 2,024,000,000 | 1,043,000,000 | -531,700,000 | 341,600,000 | 752,400,000 | 298,800,000 | |||||||||
yoy | -183.48% | -20.84% | 83.24% | -18.85% | 6.66% | -405.30% | -33.47% | -191.30% | 68.81% | -140.64% | 46.09% | -251.50% | -34.55% | -19.72% | -28.88% | 155.28% | 35.58% | -279.47% | 55.29% | -48.53% | -1.24% | -211.87% | 54.71% | 12.43% | 10.43% | 70.43% | -2.51% | 56.41% | 296.06% | -205.00% | -3582.14% | -12.28% | -52.55% | 75.80% | -102.56% | 61.49% | 37.87% | -160.90% | 19.61% | 75.40% | 18.05% | -86.65% | 104.02% | -65.72% | -44.11% | 836.75% | -20.37% | 121.19% | 7.03% | -13.89% | -34.99% | -49.47% | -8.34% | -40.01% | 2.19% | -11.41% | 66.63% | -384.37% | 395.32% | 169.01% | 249.06% | |||||||||||||
qoq | -243.10% | -48.78% | 30.68% | -12.84% | 35.69% | 18.56% | -42.13% | 14.55% | -488.42% | -125.84% | -179.41% | -311.80% | -6.50% | -7.11% | -17.65% | -8.49% | 14.69% | -17.71% | 195.60% | -51.40% | -251.81% | -171.20% | -2.03% | -6.74% | 71.98% | -1.54% | -28.80% | -8.40% | 165.42% | -43.68% | 14.24% | 131.93% | -170.36% | 1767.86% | -102.88% | 25.47% | -360.67% | -127.24% | 81.24% | 7.11% | 15.15% | -46.50% | 165.79% | -27.91% | -86.97% | 717.43% | -55.34% | 17.54% | 118.31% | -30.52% | 24.06% | -43.13% | 75.63% | -47.54% | -3.57% | 3.16% | 14.95% | -10.64% | -16.40% | 94.06% | -296.16% | -255.65% | -54.60% | 151.81% | ||||||||||
net income margin % | -26.03% | 18.07% | 33.49% | 28.01% | 32.71% | 23.96% | 18.95% | 33.86% | 30.19% | -8.38% | 29.73% | -39.74% | 19.47% | 21.81% | 21.71% | 27.03% | 27.11% | 27.79% | 34.72% | 13.55% | 26.32% | -16.73% | 23.43% | 27.61% | 26.70% | 25.56% | 15.33% | 22.70% | 26.95% | 12.44% | 18.07% | 16.31% | 7.33% | -10.03% | -0.54% | 19.60% | 16.44% | -5.88% | 20.73% | 12.24% | 12.08% | 9.56% | 18.13% | 7.02% | 10.11% | 69.80% | 8.48% | 18.33% | 16.61% | 6.90% | 10.19% | 8.23% | 14.93% | 7.73% | 15.05% | 14.56% | 14.82% | 12.30% | 14.07% | 16.66% | 9.01% | -4.40% | 3.07% | 6.63% | 2.62% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | NaN% | |
basic earnings per common share attributable to merck & co., inc. common shareholders | -1,720,000 | 1,210,000 | 2,320,000 | 1,760,000 | 2,010,000 | 1,480,000 | 1,250,000 | 2,150,000 | 1,880,000 | 157,500 | 1,870,000 | -2,350,000 | 1,110,000 | 1,260,000 | -830,000 | 1,160,000 | 1,190,000 | 1,270,000 | -570,000 | 740,000 | 1,040,000 | 1,130,000 | -760,000 | 730,000 | 640,000 | 270,000 | -380,000 | -20,000 | 710,000 | 560,000 | -210,000 | 790,000 | 440,000 | 410,000 | 350,000 | 650,000 | 240,000 | 340,000 | 2,540,000 | 310,000 | 690,000 | 580,000 | 270,000 | 380,000 | 300,000 | 530,000 | 300,000 | 570,000 | 500,000 | 550,000 | 650,000 | 340,000 | 112,500 | 110,000 | 240,000 | 100,000 | ||||||||||||||||||
earnings per common share assuming dilution attributable to merck & co., inc. common shareholders | -1,720,000 | 1,200,000 | 2,320,000 | 1,760,000 | 2,010,000 | 1,480,000 | 1,240,000 | 2,140,000 | 1,870,000 | 155,000 | 1,860,000 | -2,350,000 | 1,110,000 | 1,250,000 | -830,000 | 1,160,000 | 1,180,000 | 1,260,000 | -570,000 | 740,000 | 1,030,000 | 1,120,000 | -760,000 | 730,000 | 630,000 | 270,000 | -380,000 | -20,000 | 710,000 | 560,000 | -210,000 | 780,000 | 430,000 | 400,000 | 340,000 | 640,000 | 240,000 | 330,000 | 2,500,000 | 310,000 | 680,000 | 570,000 | 270,000 | 380,000 | 300,000 | 520,000 | 290,000 | 560,000 | 490,000 | 550,000 | 650,000 | 340,000 | 110,000 | 110,000 | 240,000 | 90,000 | ||||||||||||||||||
taxes on income | 458,000,000 | 958,000,000 | 571,000,000 | 818,000,000 | 426,000,000 | 929,000,000 | 903,000,000 | 583,000,000 | 870,000,000 | 825,000,000 | 276,000,000 | 98,000,000 | 483,000,000 | 509,000,000 | 619,000,000 | 314,750,000 | 440,000,000 | 615,000,000 | 205,000,000 | 420,500,000 | 707,000,000 | 370,000,000 | 604,000,000 | 2,917,000,000 | 251,000,000 | 488,000,000 | 447,000,000 | -769,000,000 | 699,000,000 | 295,000,000 | 494,000,000 | 423,000,000 | 4,484,000,000 | 648,000,000 | -142,000,000 | 360,000,000 | 410,000,000 | 375,000,000 | 310,000,000 | -66,000,000 | 385,000,000 | 455,000,000 | 860,000,000 | 740,000,000 | 38,000,000 | 628,000,000 | -382,000,000 | 658,000,000 | -201,200,000 | 126,000,000 | 460,600,000 | 285,600,000 | ||||||||||||||||||||||
income from continuing operations before taxes | 3,513,000,000 | 3,583,000,000 | 4,487,000,000 | 4,861,000,000 | 3,909,000,000 | 5,266,000,000 | 1,717,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
taxes on income from continuing operations | 495,000,000 | 330,000,000 | 538,000,000 | 554,000,000 | 85,000,000 | 695,000,000 | 503,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | 3,018,000,000 | 3,253,000,000 | 3,949,000,000 | 4,307,000,000 | 3,824,000,000 | 4,571,000,000 | 1,214,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations attributable to merck & co., inc. | 3,017,000,000 | 3,248,000,000 | 3,944,000,000 | 4,310,000,000 | 3,820,000,000 | 4,567,000,000 | 1,213,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operations, net of taxes and amounts attributable to noncontrolling interests | -62,000,000 | 332,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per common share attributable to merck & co., inc. common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from continuing operations | 1,180,000 | 1,280,000 | 1,560,000 | 1,700,000 | 1,510,000 | 1,810,000 | 480,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income from discontinued operations | -20,000 | 130,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per common share assuming dilution attributable to merck & co., inc. common shareholders: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: net loss attributable to noncontrolling interests | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
materials and production | 2,555,000,000 | 3,619,000,000 | 3,417,000,000 | 3,184,000,000 | 3,406,000,000 | 3,274,000,000 | 3,080,000,000 | 3,015,000,000 | 3,332,000,000 | 3,409,000,000 | 3,578,000,000 | 3,572,000,000 | 3,850,000,000 | 3,761,000,000 | 3,754,000,000 | 3,569,000,000 | 3,749,000,000 | 4,223,000,000 | 4,893,000,000 | 3,903,000,000 | 4,607,000,000 | 4,104,000,000 | 4,284,000,000 | 3,959,000,000 | 4,160,000,000 | 4,137,000,000 | 4,112,000,000 | 4,037,000,000 | 4,176,000,000 | 4,352,000,000 | 4,284,000,000 | 4,059,000,000 | 3,488,975,000 | 4,191,400,000 | 4,548,900,000 | 5,215,600,000 | ||||||||||||||||||||||||||||||||||||||
marketing and administrative | 1,864,750,000 | 2,443,000,000 | 2,508,000,000 | 2,508,000,000 | 2,579,000,000 | 2,401,000,000 | 2,438,000,000 | 2,411,000,000 | 2,593,000,000 | 2,393,000,000 | 2,458,000,000 | 2,318,000,000 | 2,615,000,000 | 2,472,000,000 | 2,624,000,000 | 2,601,000,000 | 2,925,000,000 | 2,975,000,000 | 2,973,000,000 | 2,734,000,000 | 2,982,000,000 | 2,803,000,000 | 3,140,000,000 | 2,987,000,000 | 3,390,000,000 | 3,063,000,000 | 3,249,000,000 | 3,074,000,000 | 3,704,000,000 | 3,340,000,000 | 3,525,000,000 | 3,164,000,000 | 2,416,700,000 | 3,217,900,000 | 3,202,700,000 | 3,246,200,000 | ||||||||||||||||||||||||||||||||||||||
dividends declared per common share | 480,000 | 480,000 | 352,500 | 470,000 | 470,000 | 470,000 | 345,000 | 460,000 | 460,000 | 460,000 | 337,500 | 450,000 | 450,000 | 450,000 | 330,000 | 440,000 | 440,000 | 440,000 | 322,500 | 430,000 | 430,000 | 430,000 | 315,000 | 420,000 | 420,000 | 420,000 | 285,000 | 380,000 | 380,000 | 380,000 | 285,000 | 380,000 | 380,000 | 380,000 | ||||||||||||||||||||||||||||||||||||||||
other income | 48,000,000 | 137,000,000 | 66,000,000 | 121,000,000 | 622,000,000 | 308,400,000 | 1,108,300,000 | -280,400,000 | 167,700,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity income from affiliates | -16,000,000 | -24,000,000 | -92,000,000 | -124,000,000 | -53,000,000 | -102,000,000 | -116,000,000 | -133,000,000 | -232,000,000 | -158,000,000 | -142,000,000 | -110,000,000 | -256,000,000 | -161,000,000 | -55,000,000 | -138,000,000 | -170,200,000 | -236,400,000 | -42,900,000 | -137,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per common share attributable to | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
merck & co., inc. common shareholders | 590,000 | 570,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
earnings per common share assuming dilution attributable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
to merck & co., inc. common shareholders | 580,000 | 560,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net sales | 1,124,750,000 | 4,499,000,000 | 4,647,000,000 | 4,393,000,000 | -4,575,981,498 | 4,576,000,000 | 4,921,000,000 | 4,657,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other income/(income) | 25,500,000 | 102,000,000 | 106,000,000 | 88,000,000 | 39,000,335 | -39,000,000 | 134,000,000 | 95,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
special, merger and acquisition-related charges | 7,250,000 | 29,000,000 | 29,000,000 | 75,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity income | -96,750,000 | -387,000,000 | -370,000,000 | -400,000,000 | 433,998,130 | -434,000,000 | -493,000,000 | -517,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income before income taxes | 153,000,000 | 612,000,000 | 773,000,000 | 934,000,000 | 164,500,000 | 658,000,000 | 502,000,000 | 363,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income tax expense | 24,250,000 | 97,000,000 | 102,000,000 | 129,000,000 | -68,999,854 | 69,000,000 | 66,000,000 | 72,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
preferred stock dividends | -35,900,000 | 38,000,000 | 38,000,000 | 38,000,000 | -37,999,850 | 38,000,000 | 38,000,000 | 38,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income available to common shareholders | 12,422,200,000 | 477,000,000 | 633,000,000 | 767,000,000 | 137,750,000 | 551,000,000 | 398,000,000 | 253,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
diluted earnings per common share | 72,500 | 290,000 | 380,000 | 460,000 | 85,000 | 340,000 | 240,000 | 150,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
basic earnings per common share | 72,500 | 290,000 | 380,000 | 470,000 | 85,000 | 340,000 | 250,000 | 160,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends per common share | 16,250 | 65,000 | 65,000 | 65,000 | -64,999.74 | 65,000 | 65,000 | 65,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
special and acquisition-related charges | -100,999,671 | 101,000,000 | 94,000,000 | 23,000,000 |
Balance Sheets:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-12-31 | 2009-09-30 | 2009-06-30 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 | 2007-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents | 5,327,000,000 | 14,565,000,000 | 18,169,000,000 | 8,007,000,000 | 8,629,000,000 | 13,242,000,000 | 14,593,000,000 | 11,304,000,000 | 5,579,000,000 | 6,841,000,000 | 8,605,000,000 | 5,660,000,000 | 9,707,000,000 | 12,694,000,000 | 11,145,000,000 | 9,675,000,000 | 8,556,000,000 | 8,096,000,000 | 10,016,000,000 | 8,575,000,000 | 6,981,000,000 | 8,062,000,000 | 7,356,000,000 | 11,103,000,000 | 7,425,000,000 | 9,676,000,000 | 7,869,000,000 | 6,659,000,000 | 8,076,000,000 | 7,965,000,000 | 7,826,000,000 | 5,310,000,000 | 4,483,000,000 | 6,092,000,000 | 7,901,000,000 | 7,786,000,000 | 11,708,000,000 | 6,515,000,000 | 7,907,000,000 | 6,608,000,000 | 9,716,000,000 | 8,524,000,000 | 7,548,000,000 | 6,922,000,000 | 7,980,000,000 | 7,441,000,000 | 11,370,000,000 | 9,743,000,000 | 15,828,000,000 | 15,621,000,000 | 14,090,000,000 | 15,090,000,000 | 13,024,000,000 | 13,451,000,000 | 17,360,000,000 | 16,752,000,000 | 14,656,000,000 | 13,531,000,000 | 14,253,000,000 | 12,342,000,000 | 11,695,000,000 | 10,900,000,000 | 9,874,400,000 | 8,665,600,000 | 8,236,000,000 | 9,311,400,000 | 4,312,000,000 | 2,989,000,000 | 2,845,000,000 | 3,373,000,000 | 3,159,000,000 | 2,705,000,000 | 2,454,000,000 | 2,279,000,000 |
short-term investments | 375,000,000 | 45,000,000 | 615,000,000 | 599,000,000 | 447,000,000 | 50,000,000 | 40,000,000 | 252,000,000 | 168,000,000 | 718,000,000 | 680,000,000 | 498,000,000 | 103,000,000 | 453,000,000 | 372,000,000 | 7,000,000 | 774,000,000 | 149,000,000 | 446,000,000 | 722,000,000 | 899,000,000 | 2,459,000,000 | 2,284,000,000 | 2,863,000,000 | 2,406,000,000 | 3,294,000,000 | 4,181,000,000 | 3,541,000,000 | 7,826,000,000 | 5,160,000,000 | 5,226,000,000 | 3,227,000,000 | 4,903,000,000 | 4,541,000,000 | 4,448,000,000 | 7,621,000,000 | 8,278,000,000 | 2,977,000,000 | 3,652,000,000 | 4,685,000,000 | 1,865,000,000 | 4,079,000,000 | 3,008,000,000 | 2,998,000,000 | 2,690,000,000 | 757,000,000 | 698,000,000 | 910,000,000 | 1,441,000,000 | 1,323,000,000 | 1,639,000,000 | 1,334,000,000 | 1,301,000,000 | 750,400,000 | 1,277,000,000 | 1,541,300,000 | 293,100,000 | 487,000,000 | 1,411,000,000 | 708,000,000 | 5,000,000 | 6,000,000 | 22,000,000 | 7,000,000 | 32,000,000 | |||||||||
accounts receivable | 12,210,000,000 | 11,775,000,000 | 12,120,000,000 | 11,846,000,000 | 10,790,000,000 | 10,278,000,000 | 11,381,000,000 | 11,642,000,000 | 11,366,000,000 | 10,349,000,000 | 10,394,000,000 | 11,030,000,000 | 10,415,000,000 | 9,450,000,000 | 9,482,000,000 | 9,643,000,000 | 9,828,000,000 | 9,230,000,000 | 8,571,000,000 | 7,843,000,000 | 8,235,000,000 | 7,851,000,000 | 8,422,000,000 | 7,577,000,000 | 8,182,000,000 | 6,778,000,000 | 8,442,000,000 | 7,964,000,000 | 7,608,000,000 | 7,071,000,000 | 7,374,000,000 | 7,287,000,000 | 7,245,000,000 | 6,873,000,000 | 7,671,000,000 | 7,439,000,000 | 7,066,000,000 | 7,018,000,000 | 7,364,000,000 | 6,916,000,000 | 6,850,000,000 | 6,484,000,000 | 6,414,000,000 | 6,510,000,000 | 6,670,000,000 | 6,626,000,000 | 6,515,000,000 | 7,022,000,000 | 7,188,000,000 | 7,184,000,000 | 7,578,000,000 | 7,779,000,000 | 7,965,000,000 | 7,672,000,000 | 7,952,000,000 | 8,152,000,000 | 8,726,000,000 | 8,261,000,000 | 8,136,000,000 | 8,475,000,000 | 7,955,000,000 | 7,344,000,000 | 7,297,500,000 | 6,276,100,000 | 7,497,700,000 | 6,602,900,000 | 3,127,000,000 | 3,164,000,000 | 2,953,000,000 | 2,920,000,000 | 3,381,000,000 | 3,363,000,000 | ||
inventories | 6,479,000,000 | 6,658,000,000 | 6,444,000,000 | 6,601,000,000 | 6,196,000,000 | 6,109,000,000 | 6,244,000,000 | 6,469,000,000 | 6,510,000,000 | 6,358,000,000 | 6,131,000,000 | 5,930,000,000 | 5,863,000,000 | 5,911,000,000 | 5,614,000,000 | 5,535,000,000 | 5,774,000,000 | 5,953,000,000 | 5,603,000,000 | 5,499,000,000 | 6,402,000,000 | 6,310,000,000 | 6,128,000,000 | 6,056,000,000 | 5,846,000,000 | 5,978,000,000 | 5,855,000,000 | 5,847,000,000 | 5,712,000,000 | 5,440,000,000 | 5,416,000,000 | 5,178,000,000 | 5,382,000,000 | 5,096,000,000 | 5,263,000,000 | 5,407,000,000 | 5,146,000,000 | 4,866,000,000 | 5,244,000,000 | 5,248,000,000 | 5,102,000,000 | 4,700,000,000 | 5,123,000,000 | 5,306,000,000 | 5,539,000,000 | 5,571,000,000 | 5,819,000,000 | 6,136,000,000 | 6,376,000,000 | 6,226,000,000 | 6,741,000,000 | 6,766,000,000 | 6,773,000,000 | 6,535,000,000 | 6,731,000,000 | 6,249,000,000 | 6,339,000,000 | 6,254,000,000 | 6,239,000,000 | 6,225,000,000 | 6,057,000,000 | 5,868,000,000 | 6,263,600,000 | 6,244,200,000 | 6,825,400,000 | 3,459,000,000 | 3,478,000,000 | 3,158,000,000 | 3,114,000,000 | 3,183,000,000 | 3,478,000,000 | 3,741,000,000 | 4,073,000,000 | |
other current assets | 10,624,000,000 | 10,518,000,000 | 10,779,000,000 | 9,996,000,000 | 9,289,000,000 | 8,706,000,000 | 8,143,000,000 | 8,740,000,000 | 7,950,000,000 | 8,368,000,000 | 6,656,000,000 | 6,639,000,000 | 6,737,000,000 | 7,169,000,000 | 7,217,000,000 | 6,810,000,000 | 6,654,000,000 | 6,987,000,000 | 6,868,000,000 | 6,748,000,000 | 5,291,000,000 | 5,541,000,000 | 4,671,000,000 | 4,607,000,000 | 4,714,000,000 | 4,277,000,000 | 3,827,000,000 | 3,382,000,000 | 3,233,000,000 | 4,500,000,000 | 3,761,000,000 | 4,005,000,000 | 4,112,000,000 | 4,299,000,000 | 3,790,000,000 | 3,354,000,000 | 4,069,000,000 | 4,389,000,000 | 3,765,000,000 | 3,928,000,000 | 3,877,000,000 | 5,153,000,000 | ||||||||||||||||||||||||||||||||
total current assets | 35,015,000,000 | 43,516,000,000 | 47,557,000,000 | 37,065,000,000 | 35,503,000,000 | 38,782,000,000 | 40,361,000,000 | 38,205,000,000 | 31,445,000,000 | 32,168,000,000 | 31,954,000,000 | 29,977,000,000 | 33,402,000,000 | 35,722,000,000 | 33,561,000,000 | 32,116,000,000 | 31,184,000,000 | 30,266,000,000 | 31,058,000,000 | 28,665,000,000 | 26,909,000,000 | 27,764,000,000 | 26,577,000,000 | 29,343,000,000 | 26,174,000,000 | 27,483,000,000 | 26,142,000,000 | 24,298,000,000 | 25,351,000,000 | 25,875,000,000 | 26,836,000,000 | 24,064,000,000 | 24,085,000,000 | 24,766,000,000 | 27,919,000,000 | 28,167,000,000 | 31,530,000,000 | 30,614,000,000 | 29,440,000,000 | 27,926,000,000 | 28,772,000,000 | 29,764,000,000 | 28,567,000,000 | 28,319,000,000 | 32,927,000,000 | 33,173,000,000 | 34,723,000,000 | 33,587,000,000 | 41,240,000,000 | 35,685,000,000 | 37,765,000,000 | 36,995,000,000 | 35,244,000,000 | 34,857,000,000 | 36,229,000,000 | 35,639,000,000 | 34,344,000,000 | 33,181,000,000 | 34,109,000,000 | 32,368,000,000 | 31,024,000,000 | 29,064,000,000 | 27,756,000,000 | 26,253,600,000 | 28,244,900,000 | 28,428,600,000 | 13,166,000,000 | 12,676,000,000 | 11,344,000,000 | 10,971,000,000 | 10,969,000,000 | 11,366,000,000 | 11,224,000,000 | 10,846,000,000 |
investments | 1,105,000,000 | 956,000,000 | 1,117,000,000 | 774,000,000 | 616,000,000 | 463,000,000 | 575,000,000 | 357,000,000 | 280,000,000 | 252,000,000 | 1,306,000,000 | 1,214,000,000 | 1,290,000,000 | 1,015,000,000 | 984,000,000 | 238,000,000 | 316,000,000 | 370,000,000 | 435,000,000 | 411,000,000 | 544,000,000 | 785,000,000 | 1,372,000,000 | 1,251,000,000 | 555,000,000 | 1,469,000,000 | 2,111,000,000 | 3,779,000,000 | 5,621,000,000 | 6,233,000,000 | 7,606,000,000 | 10,033,000,000 | 11,033,000,000 | 12,125,000,000 | 12,206,000,000 | 12,138,000,000 | 11,896,000,000 | 11,416,000,000 | 11,657,000,000 | 11,879,000,000 | 12,554,000,000 | 13,039,000,000 | 13,080,000,000 | 13,333,000,000 | 13,092,000,000 | 13,515,000,000 | 13,492,000,000 | 12,618,000,000 | 11,456,000,000 | 9,770,000,000 | 9,198,000,000 | 8,555,000,000 | 7,948,000,000 | 7,305,000,000 | 5,560,000,000 | 4,085,000,000 | 3,972,000,000 | 3,458,000,000 | 2,423,000,000 | 2,175,000,000 | 2,084,000,000 | 2,175,000,000 | 2,137,500,000 | 2,045,600,000 | 1,995,000,000 | 432,300,000 | ||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 22,288 in 2026 and 21,914 in 2025 | 25,433,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
goodwill | 21,581,000,000 | 21,579,000,000 | 21,587,000,000 | 21,591,000,000 | 21,684,000,000 | 21,668,000,000 | 21,697,000,000 | 21,161,000,000 | 21,181,000,000 | 21,197,000,000 | 21,183,000,000 | 21,195,000,000 | 21,209,000,000 | 21,204,000,000 | 21,160,000,000 | 21,213,000,000 | 21,258,000,000 | 21,264,000,000 | 18,862,000,000 | 18,873,000,000 | 20,212,000,000 | 20,238,000,000 | 20,248,000,000 | 20,067,000,000 | 19,767,000,000 | 19,425,000,000 | 19,480,000,000 | 19,490,000,000 | 18,170,000,000 | 18,253,000,000 | 18,258,000,000 | 18,274,000,000 | 18,304,000,000 | 18,284,000,000 | 18,340,000,000 | 18,358,000,000 | 18,358,000,000 | 18,162,000,000 | 18,260,000,000 | 17,809,000,000 | 17,784,000,000 | 17,723,000,000 | 17,761,000,000 | 17,707,000,000 | 17,740,000,000 | 12,992,000,000 | 13,171,000,000 | 11,789,000,000 | 12,120,000,000 | 12,301,000,000 | 12,121,000,000 | 12,198,000,000 | 12,207,000,000 | 12,134,000,000 | 12,168,000,000 | 12,158,000,000 | 12,156,000,000 | 12,155,000,000 | 12,228,000,000 | 12,382,000,000 | 12,207,000,000 | 12,378,000,000 | 12,480,800,000 | 12,225,500,000 | 12,266,200,000 | 11,923,100,000 | 2,879,000,000 | 2,802,000,000 | 2,667,000,000 | 2,778,000,000 | 2,870,000,000 | 3,064,000,000 | 3,053,000,000 | 2,937,000,000 |
other intangibles | 25,745,000,000 | 26,681,000,000 | 15,313,000,000 | 15,193,000,000 | 15,758,000,000 | 16,370,000,000 | 17,010,000,000 | 16,984,000,000 | 17,572,000,000 | 18,011,000,000 | 19,199,000,000 | 19,665,000,000 | 19,857,000,000 | 20,269,000,000 | 21,368,000,000 | 22,497,000,000 | 23,022,000,000 | 22,933,000,000 | 13,384,000,000 | 13,622,000,000 | 14,401,000,000 | 14,604,000,000 | 16,677,000,000 | 16,566,000,000 | 16,096,000,000 | 14,196,000,000 | 12,307,000,000 | 13,381,000,000 | 10,999,000,000 | 11,431,000,000 | 12,175,000,000 | 12,898,000,000 | 13,500,000,000 | 14,183,000,000 | 15,138,000,000 | 16,119,000,000 | 16,863,000,000 | 17,305,000,000 | 20,506,000,000 | 20,315,000,000 | 21,364,000,000 | 22,602,000,000 | 23,724,000,000 | 24,750,000,000 | 26,080,000,000 | 20,386,000,000 | 20,395,000,000 | 18,830,000,000 | 20,517,000,000 | 23,801,000,000 | 25,002,000,000 | 26,333,000,000 | 28,108,000,000 | 29,083,000,000 | 30,325,000,000 | 31,620,000,000 | 33,000,000,000 | 34,302,000,000 | 35,822,000,000 | 37,065,000,000 | 37,906,000,000 | 39,456,000,000 | 42,954,400,000 | 43,281,400,000 | 45,574,900,000 | 47,655,800,000 | ||||||||
other assets | 19,806,000,000 | 18,818,000,000 | 18,333,000,000 | 17,664,000,000 | 16,768,000,000 | 16,044,000,000 | 14,443,000,000 | 12,702,000,000 | 12,326,000,000 | 11,996,000,000 | 10,559,000,000 | 10,187,000,000 | 10,280,000,000 | 9,528,000,000 | 9,584,000,000 | 10,972,000,000 | 11,141,000,000 | 11,582,000,000 | 11,190,000,000 | 11,053,000,000 | 10,486,000,000 | 10,211,000,000 | 8,007,000,000 | 7,599,000,000 | 7,052,000,000 | 6,771,000,000 | 9,004,000,000 | 9,155,000,000 | 8,707,000,000 | 7,554,000,000 | 7,500,000,000 | 7,145,000,000 | 6,558,000,000 | 6,075,000,000 | 5,884,000,000 | 5,928,000,000 | 5,872,000,000 | 5,854,000,000 | 6,443,000,000 | 6,559,000,000 | 5,921,000,000 | 6,144,000,000 | 5,618,000,000 | 5,843,000,000 | 5,596,000,000 | 5,133,000,000 | 6,589,000,000 | 7,143,000,000 | 8,831,000,000 | 9,115,000,000 | 7,010,000,000 | 7,112,000,000 | 6,891,000,000 | 6,723,000,000 | 6,135,000,000 | 6,156,000,000 | 5,913,000,000 | 5,735,000,000 | 5,569,000,000 | 5,534,000,000 | 5,811,000,000 | 5,626,000,000 | 5,395,600,000 | 5,030,200,000 | 5,527,800,000 | 5,376,400,000 | 1,597,000,000 | 1,247,000,000 | 1,284,000,000 | 1,381,000,000 | 1,343,000,000 | 1,403,000,000 | 1,389,000,000 | 1,353,000,000 |
liabilities and equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loans payable and current portion of long-term debt | 2,444,000,000 | 2,589,000,000 | 1,405,000,000 | 1,434,000,000 | 1,360,000,000 | 2,649,000,000 | 3,149,000,000 | 3,071,000,000 | 3,077,000,000 | 1,372,000,000 | 887,000,000 | 2,839,000,000 | 2,672,000,000 | 1,946,000,000 | 1,936,000,000 | 2,979,000,000 | 1,208,000,000 | 2,412,000,000 | 3,534,000,000 | 2,488,000,000 | 7,251,000,000 | 6,431,000,000 | 2,420,000,000 | 4,718,000,000 | 6,361,000,000 | 3,610,000,000 | 3,411,000,000 | 3,816,000,000 | 3,175,000,000 | 5,308,000,000 | 3,656,000,000 | 3,379,000,000 | 2,055,000,000 | 3,057,000,000 | 5,157,000,000 | 3,181,000,000 | 5,037,000,000 | 568,000,000 | 1,487,000,000 | 644,000,000 | 2,113,000,000 | 2,585,000,000 | 2,543,000,000 | 2,483,000,000 | 4,728,000,000 | 2,704,000,000 | 9,275,000,000 | 4,477,000,000 | 8,559,000,000 | 4,521,000,000 | 3,976,000,000 | 5,582,000,000 | 4,736,000,000 | 4,315,000,000 | 2,029,000,000 | 3,922,000,000 | 2,930,000,000 | 1,990,000,000 | 2,455,000,000 | 2,523,000,000 | 2,202,000,000 | 2,400,000,000 | 4,116,000,000 | 4,147,300,000 | 3,822,400,000 | 1,379,200,000 | ||||||||
trade accounts payable | 3,863,000,000 | 4,404,000,000 | 4,147,000,000 | 3,892,000,000 | 3,784,000,000 | 4,079,000,000 | 3,586,000,000 | 3,519,000,000 | 3,514,000,000 | 3,922,000,000 | 3,509,000,000 | 3,442,000,000 | 3,680,000,000 | 4,264,000,000 | 3,371,000,000 | 3,482,000,000 | 3,715,000,000 | 4,609,000,000 | 3,366,000,000 | 3,897,000,000 | 4,034,000,000 | 4,594,000,000 | 3,744,000,000 | 3,448,000,000 | 3,572,000,000 | 3,738,000,000 | 3,198,000,000 | 3,142,000,000 | 3,018,000,000 | 3,318,000,000 | 3,091,000,000 | 3,024,000,000 | 3,162,000,000 | 3,102,000,000 | 2,620,000,000 | 2,934,000,000 | 2,484,000,000 | 2,807,000,000 | 2,481,000,000 | 2,514,000,000 | 2,241,000,000 | 2,533,000,000 | 2,023,000,000 | 2,335,000,000 | 2,091,000,000 | 2,625,000,000 | 2,279,000,000 | 2,326,000,000 | 2,434,000,000 | 2,274,000,000 | 2,469,000,000 | 2,253,000,000 | 2,084,000,000 | 1,753,000,000 | 1,804,000,000 | 1,674,000,000 | 2,358,000,000 | 2,462,000,000 | 2,282,000,000 | 2,143,000,000 | 2,402,000,000 | 2,308,000,000 | 2,242,400,000 | 2,171,500,000 | 2,074,900,000 | 2,236,900,000 | ||||||||
accrued and other current liabilities | 14,549,000,000 | 14,468,000,000 | 16,186,000,000 | 14,502,000,000 | 12,772,000,000 | 15,694,000,000 | 16,539,000,000 | 14,712,000,000 | 14,102,000,000 | 15,766,000,000 | 14,840,000,000 | 13,747,000,000 | 13,000,000,000 | 14,159,000,000 | 14,222,000,000 | 13,501,000,000 | 14,051,000,000 | 13,859,000,000 | 14,214,000,000 | 12,888,000,000 | 11,911,000,000 | 13,053,000,000 | 11,690,000,000 | 11,182,000,000 | 10,932,000,000 | 12,549,000,000 | 11,768,000,000 | 11,054,000,000 | 10,081,000,000 | 10,151,000,000 | 9,776,000,000 | 9,755,000,000 | 9,709,000,000 | 10,427,000,000 | 9,992,000,000 | 9,363,000,000 | 8,658,000,000 | 10,274,000,000 | 9,087,000,000 | 9,255,000,000 | 10,043,000,000 | 11,216,000,000 | 9,610,000,000 | 9,517,000,000 | 9,867,000,000 | 10,523,000,000 | 9,808,000,000 | 8,829,000,000 | 8,707,000,000 | 9,501,000,000 | 9,183,000,000 | 8,872,000,000 | 9,569,000,000 | 9,737,000,000 | 8,923,000,000 | 8,917,000,000 | 8,823,000,000 | 9,731,000,000 | 9,228,000,000 | 8,747,000,000 | 8,555,000,000 | 8,514,000,000 | 8,159,500,000 | 6,834,400,000 | 8,439,000,000 | 9,453,800,000 | ||||||||
income taxes payable | 3,946,000,000 | 4,726,000,000 | 4,848,000,000 | 4,156,000,000 | 5,181,000,000 | 3,914,000,000 | 4,330,000,000 | 2,777,000,000 | 2,398,000,000 | 2,649,000,000 | 1,981,000,000 | 1,489,000,000 | 1,872,000,000 | 1,986,000,000 | 1,698,000,000 | 1,438,000,000 | 1,571,000,000 | 1,224,000,000 | 954,000,000 | 971,000,000 | 1,490,000,000 | 1,575,000,000 | 984,000,000 | 1,266,000,000 | 1,033,000,000 | 736,000,000 | 873,000,000 | 634,000,000 | 807,000,000 | 1,971,000,000 | 759,000,000 | 661,000,000 | 717,000,000 | 708,000,000 | 396,000,000 | 1,979,000,000 | 2,330,000,000 | 2,239,000,000 | 1,208,000,000 | 1,213,000,000 | 1,864,000,000 | 1,560,000,000 | 2,119,000,000 | 1,878,000,000 | 2,450,000,000 | 1,606,000,000 | 2,467,000,000 | 192,000,000 | 595,000,000 | 251,000,000 | 1,298,000,000 | 409,000,000 | 1,075,000,000 | 1,200,000,000 | 1,512,000,000 | 1,091,000,000 | 1,190,000,000 | 781,000,000 | 1,462,000,000 | 1,174,000,000 | 1,326,000,000 | 1,243,000,000 | 1,629,700,000 | 879,400,000 | 723,000,000 | 1,285,200,000 | ||||||||
dividends payable | 2,143,000,000 | 2,140,000,000 | 2,042,000,000 | 2,053,000,000 | 2,077,000,000 | 2,084,000,000 | 1,982,000,000 | 1,981,000,000 | 2,008,000,000 | 1,985,000,000 | 1,877,000,000 | 1,877,000,000 | 1,907,000,000 | 1,884,000,000 | 1,771,000,000 | 1,768,000,000 | 1,771,000,000 | 1,768,000,000 | 1,660,000,000 | 1,662,000,000 | 1,675,000,000 | 1,674,000,000 | 1,567,000,000 | 1,564,000,000 | 1,585,000,000 | 1,587,000,000 | 1,434,000,000 | 1,439,000,000 | 1,462,000,000 | 1,458,000,000 | 1,304,000,000 | 1,309,000,000 | 1,317,000,000 | 1,320,000,000 | 1,302,000,000 | 1,301,000,000 | 1,314,000,000 | 1,316,000,000 | 1,292,000,000 | 1,292,000,000 | 1,307,000,000 | 1,309,000,000 | 1,288,000,000 | 1,295,000,000 | 1,306,000,000 | 1,308,000,000 | 1,288,000,000 | 1,303,000,000 | 1,327,000,000 | 1,321,000,000 | 1,289,000,000 | 1,286,000,000 | 1,338,000,000 | 1,343,000,000 | 1,315,000,000 | 1,308,000,000 | 1,281,000,000 | 1,281,000,000 | 1,166,000,000 | 1,176,000,000 | 1,177,000,000 | 1,176,000,000 | 1,175,700,000 | 1,182,000,000 | 1,189,800,000 | 1,189,000,000 | ||||||||
total current liabilities | 26,945,000,000 | 28,327,000,000 | 28,628,000,000 | 26,037,000,000 | 25,174,000,000 | 28,420,000,000 | 29,586,000,000 | 26,060,000,000 | 25,099,000,000 | 25,694,000,000 | 23,094,000,000 | 23,394,000,000 | 23,131,000,000 | 24,239,000,000 | 22,998,000,000 | 23,168,000,000 | 22,316,000,000 | 23,872,000,000 | 23,728,000,000 | 21,906,000,000 | 26,361,000,000 | 27,327,000,000 | 20,405,000,000 | 22,178,000,000 | 23,483,000,000 | 22,220,000,000 | 20,684,000,000 | 20,085,000,000 | 18,543,000,000 | 22,206,000,000 | 18,586,000,000 | 18,128,000,000 | 16,960,000,000 | 18,614,000,000 | 19,467,000,000 | 18,758,000,000 | 19,823,000,000 | 17,204,000,000 | 15,555,000,000 | 14,918,000,000 | 17,568,000,000 | 19,203,000,000 | 17,583,000,000 | 17,508,000,000 | 20,442,000,000 | 18,766,000,000 | 25,927,000,000 | 17,928,000,000 | 22,470,000,000 | 17,868,000,000 | 18,215,000,000 | 18,402,000,000 | 18,802,000,000 | 18,348,000,000 | 15,583,000,000 | 16,912,000,000 | 16,582,000,000 | 16,245,000,000 | 16,593,000,000 | 15,763,000,000 | 15,662,000,000 | 15,641,000,000 | 17,323,300,000 | 15,420,600,000 | 16,455,300,000 | 15,750,700,000 | 5,089,000,000 | 5,194,000,000 | 4,961,000,000 | 5,193,000,000 | 5,416,000,000 | 5,758,000,000 | 5,823,000,000 | 6,043,000,000 |
long-term debt | 46,673,000,000 | 46,750,000,000 | 39,969,000,000 | 33,968,000,000 | 33,484,000,000 | 34,462,000,000 | 34,982,000,000 | 34,717,000,000 | 31,142,000,000 | 33,683,000,000 | 33,972,000,000 | 34,072,000,000 | 28,074,000,000 | 28,745,000,000 | 28,482,000,000 | 28,684,000,000 | 30,586,000,000 | 30,690,000,000 | 22,907,000,000 | 24,033,000,000 | 24,002,000,000 | 25,360,000,000 | 26,321,000,000 | 26,156,000,000 | 21,637,000,000 | 22,736,000,000 | 22,677,000,000 | 22,771,000,000 | 22,721,000,000 | 19,806,000,000 | 19,936,000,000 | 19,959,000,000 | 21,501,000,000 | 21,353,000,000 | 21,838,000,000 | 21,706,000,000 | 23,437,000,000 | 24,274,000,000 | 23,656,000,000 | 23,642,000,000 | 23,656,000,000 | 23,929,000,000 | 24,124,000,000 | 24,069,000,000 | 25,506,000,000 | 18,699,000,000 | 18,566,000,000 | 18,590,000,000 | 19,589,000,000 | 20,539,000,000 | 22,647,000,000 | 22,526,000,000 | 16,089,000,000 | 16,254,000,000 | 17,571,000,000 | 15,057,000,000 | 15,228,000,000 | 15,525,000,000 | 15,692,000,000 | 15,783,000,000 | 15,644,000,000 | 15,482,000,000 | 14,031,900,000 | 13,835,300,000 | 15,281,100,000 | 16,074,900,000 | 8,033,000,000 | 7,908,000,000 | 7,685,000,000 | 7,931,000,000 | 8,166,000,000 | 9,015,000,000 | 9,349,000,000 | 9,019,000,000 |
deferred income taxes | 1,494,000,000 | 1,439,000,000 | 1,381,000,000 | 1,427,000,000 | 1,409,000,000 | 1,387,000,000 | 864,000,000 | 876,000,000 | 922,000,000 | 871,000,000 | 1,018,000,000 | 996,000,000 | 1,442,000,000 | 1,795,000,000 | 2,417,000,000 | 2,974,000,000 | 3,071,000,000 | 3,441,000,000 | 1,527,000,000 | 1,489,000,000 | 1,204,000,000 | 1,015,000,000 | 1,777,000,000 | 2,091,000,000 | 1,943,000,000 | 1,470,000,000 | 1,960,000,000 | 2,089,000,000 | 1,835,000,000 | 1,702,000,000 | 2,065,000,000 | 2,159,000,000 | 2,206,000,000 | 2,219,000,000 | 4,159,000,000 | 4,560,000,000 | 4,889,000,000 | 5,077,000,000 | 6,374,000,000 | 6,091,000,000 | 6,256,000,000 | 6,535,000,000 | 5,959,000,000 | 6,454,000,000 | 6,803,000,000 | 4,266,000,000 | 4,987,000,000 | 4,651,000,000 | 5,881,000,000 | 6,776,000,000 | 578,000,000 | 515,000,000 | 485,000,000 | 435,000,000 | 509,000,000 | 518,000,000 | 442,000,000 | 349,000,000 | ||||||||||||||||
other noncurrent liabilities | 7,642,000,000 | 7,688,000,000 | 7,661,000,000 | 7,031,000,000 | 6,655,000,000 | 6,465,000,000 | 7,540,000,000 | 7,329,000,000 | 8,262,000,000 | 8,792,000,000 | 7,343,000,000 | 7,265,000,000 | 8,244,000,000 | 8,323,000,000 | 8,660,000,000 | 8,951,000,000 | 9,742,000,000 | 9,434,000,000 | 9,469,000,000 | 9,872,000,000 | 12,241,000,000 | 12,482,000,000 | 12,027,000,000 | 12,446,000,000 | 11,550,000,000 | 11,970,000,000 | 11,085,000,000 | 11,283,000,000 | 11,585,000,000 | 12,041,000,000 | 11,887,000,000 | 12,028,000,000 | 11,473,000,000 | 11,117,000,000 | 7,713,000,000 | 8,068,000,000 | 8,324,000,000 | 8,514,000,000 | 8,793,000,000 | 8,378,000,000 | 7,374,000,000 | 7,345,000,000 | 7,887,000,000 | 7,913,000,000 | 7,677,000,000 | 7,813,000,000 | 6,968,000,000 | 8,175,000,000 | 7,956,000,000 | 8,136,000,000 | ||||||||||||||||||||||||
merck & co., inc. stockholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common stock | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | 1,788,000,000 | |||||||||||||||||||
other paid-in capital | 45,176,000,000 | 45,029,000,000 | 44,832,000,000 | 44,644,000,000 | 44,816,000,000 | 44,704,000,000 | 44,530,000,000 | 44,362,000,000 | 44,598,000,000 | 44,509,000,000 | 44,358,000,000 | 44,219,000,000 | 44,467,000,000 | 44,379,000,000 | 44,243,000,000 | 44,115,000,000 | 44,275,000,000 | 44,238,000,000 | 44,149,000,000 | 44,039,000,000 | 39,613,000,000 | 39,588,000,000 | 39,489,000,000 | 39,373,000,000 | 39,697,000,000 | 39,660,000,000 | 39,561,000,000 | 39,484,000,000 | 38,768,000,000 | 38,808,000,000 | 39,762,000,000 | 39,741,000,000 | 39,874,000,000 | 39,902,000,000 | 39,823,000,000 | 39,776,000,000 | 39,899,000,000 | 39,939,000,000 | 39,897,000,000 | 39,911,000,000 | 40,145,000,000 | 40,222,000,000 | 40,139,000,000 | 40,114,000,000 | 40,355,000,000 | 40,423,000,000 | 40,340,000,000 | 40,199,000,000 | 40,450,000,000 | 40,508,000,000 | 39,909,000,000 | 39,891,000,000 | 40,727,000,000 | 40,646,000,000 | 40,471,000,000 | 40,550,000,000 | 40,652,000,000 | 40,663,000,000 | 40,717,000,000 | 40,657,000,000 | 40,690,000,000 | 40,701,000,000 | 40,556,700,000 | 40,337,700,000 | 40,196,600,000 | 39,682,600,000 | ||||||||
retained earnings | 66,721,000,000 | 73,075,000,000 | 72,231,000,000 | 68,477,000,000 | 66,097,000,000 | 63,069,000,000 | 61,384,000,000 | 60,187,000,000 | 56,697,000,000 | 53,895,000,000 | 57,082,000,000 | 54,198,000,000 | 62,039,000,000 | 61,081,000,000 | 59,928,000,000 | 58,437,000,000 | 56,252,000,000 | 53,696,000,000 | 51,691,000,000 | 48,777,000,000 | 48,888,000,000 | 47,362,000,000 | 51,107,000,000 | 49,724,000,000 | 48,272,000,000 | 46,602,000,000 | 45,804,000,000 | 45,295,000,000 | 44,065,000,000 | 42,579,000,000 | 42,189,000,000 | 41,523,000,000 | 41,107,000,000 | 41,350,000,000 | 43,701,000,000 | 45,046,000,000 | 44,387,000,000 | 44,133,000,000 | 46,028,000,000 | 45,121,000,000 | 45,192,000,000 | 45,348,000,000 | 45,660,000,000 | 45,103,000,000 | 45,692,000,000 | 46,021,000,000 | 39,989,000,000 | 40,366,000,000 | 39,661,000,000 | 39,257,000,000 | 39,773,000,000 | 39,915,000,000 | 40,272,000,000 | 39,985,000,000 | 40,390,000,000 | 39,950,000,000 | 39,441,000,000 | 38,990,000,000 | 38,763,000,000 | 38,243,000,000 | 37,400,000,000 | 37,536,000,000 | 39,245,400,000 | 40,081,800,000 | 40,511,400,000 | 41,404,900,000 | 10,737,000,000 | 10,368,000,000 | 9,842,000,000 | 9,181,000,000 | 8,738,000,000 | 8,293,000,000 | 8,001,000,000 | 7,856,000,000 |
accumulated other comprehensive loss | -4,060,000,000 | -4,287,000,000 | -5,202,000,000 | -5,421,000,000 | -4,965,000,000 | -4,945,000,000 | -5,371,000,000 | -5,361,000,000 | -5,274,000,000 | -5,161,000,000 | -4,916,000,000 | -4,900,000,000 | -4,883,000,000 | -4,768,000,000 | -4,743,000,000 | -4,327,000,000 | -4,369,000,000 | -4,429,000,000 | -4,590,000,000 | -4,628,000,000 | -6,622,000,000 | -6,634,000,000 | -6,383,000,000 | -6,393,000,000 | -6,391,000,000 | -6,193,000,000 | -5,390,000,000 | -5,362,000,000 | -5,346,000,000 | -5,545,000,000 | -5,151,000,000 | -5,122,000,000 | -5,060,000,000 | -4,910,000,000 | -4,945,000,000 | -5,094,000,000 | -5,080,000,000 | -5,226,000,000 | -4,252,000,000 | -4,086,000,000 | -4,194,000,000 | -4,148,000,000 | -4,573,000,000 | -4,332,000,000 | -4,167,000,000 | -4,323,000,000 | -2,998,000,000 | -2,444,000,000 | -2,179,000,000 | -2,197,000,000 | -4,698,000,000 | -4,760,000,000 | -4,629,000,000 | -4,682,000,000 | -3,040,000,000 | -3,126,000,000 | -3,217,000,000 | -3,132,000,000 | -2,713,000,000 | -2,776,000,000 | -3,170,000,000 | -3,216,000,000 | -3,490,000,000 | -4,658,700,000 | -3,571,600,000 | -2,766,500,000 | -1,360,000,000 | -1,710,000,000 | -2,352,000,000 | -1,913,000,000 | -831,000,000 | -89,000,000 | -93,000,000 | -534,000,000 |
less treasury stock, at cost:1,107,410,143 shares in 2026 and 1,102,476,756 shares in 2025 | 63,747,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total merck & co., inc. stockholders’ equity | 45,878,000,000 | 52,606,000,000 | 51,850,000,000 | 48,993,000,000 | 48,335,000,000 | 46,313,000,000 | 44,502,000,000 | 43,582,000,000 | 40,364,000,000 | 37,581,000,000 | 41,246,000,000 | 38,693,000,000 | 46,834,000,000 | 45,991,000,000 | 44,458,000,000 | 43,243,000,000 | 40,883,000,000 | 38,184,000,000 | 35,794,000,000 | 33,294,000,000 | 26,945,000,000 | 25,317,000,000 | 29,186,000,000 | 27,642,000,000 | 26,205,000,000 | 25,907,000,000 | 26,838,000,000 | 27,635,000,000 | 27,539,000,000 | 26,701,000,000 | 32,422,000,000 | 32,529,000,000 | 33,668,000,000 | 34,336,000,000 | 38,248,000,000 | 39,463,000,000 | 39,837,000,000 | 40,088,000,000 | 43,744,000,000 | 43,357,000,000 | 43,806,000,000 | 44,676,000,000 | 45,587,000,000 | 46,448,000,000 | 47,765,000,000 | 48,647,000,000 | 45,224,000,000 | 48,358,000,000 | 49,975,000,000 | 49,765,000,000 | 47,419,000,000 | 47,500,000,000 | 53,029,000,000 | 53,020,000,000 | 55,747,000,000 | 55,194,000,000 | 54,860,000,000 | 54,517,000,000 | 55,140,000,000 | 55,496,000,000 | 54,384,000,000 | 54,376,000,000 | 55,592,800,000 | 55,231,700,000 | 57,878,100,000 | 59,058,000,000 | ||||||||
noncontrolling interests | 53,000,000 | 56,000,000 | 57,000,000 | 67,000,000 | 65,000,000 | 59,000,000 | 58,000,000 | 66,000,000 | 60,000,000 | 54,000,000 | 54,000,000 | 49,000,000 | 71,000,000 | 67,000,000 | 66,000,000 | 75,000,000 | 70,000,000 | 73,000,000 | 69,000,000 | 94,000,000 | 94,000,000 | 87,000,000 | 84,000,000 | 102,000,000 | 95,000,000 | 94,000,000 | 87,000,000 | 102,000,000 | 131,000,000 | 181,000,000 | 234,000,000 | 237,000,000 | 233,000,000 | 233,000,000 | 251,000,000 | 249,000,000 | 251,000,000 | 220,000,000 | 213,000,000 | 89,000,000 | 95,000,000 | 91,000,000 | 92,000,000 | 190,000,000 | 152,000,000 | 144,000,000 | 136,000,000 | 158,000,000 | 2,589,000,000 | 2,561,000,000 | 2,587,000,000 | 2,605,000,000 | 2,577,000,000 | 2,443,000,000 | 2,465,000,000 | 2,479,000,000 | 2,454,000,000 | 2,426,000,000 | 2,456,000,000 | 2,426,000,000 | 2,455,000,000 | 2,429,000,000 | 2,455,500,000 | 2,434,000,000 | 2,465,100,000 | 2,434,600,000 | ||||||||
total equity | 45,931,000,000 | 52,662,000,000 | 51,907,000,000 | 49,060,000,000 | 48,400,000,000 | 46,372,000,000 | 44,560,000,000 | 43,648,000,000 | 40,424,000,000 | 37,635,000,000 | 41,300,000,000 | 38,742,000,000 | 46,905,000,000 | 46,058,000,000 | 44,524,000,000 | 43,318,000,000 | 40,953,000,000 | 38,257,000,000 | 35,863,000,000 | 33,388,000,000 | 27,039,000,000 | 25,404,000,000 | 29,270,000,000 | 27,744,000,000 | 26,300,000,000 | 26,001,000,000 | 26,925,000,000 | 27,737,000,000 | 27,670,000,000 | 26,882,000,000 | 32,656,000,000 | 32,766,000,000 | 33,901,000,000 | 34,569,000,000 | 38,499,000,000 | 39,712,000,000 | 40,088,000,000 | 40,308,000,000 | 43,957,000,000 | 43,446,000,000 | 43,901,000,000 | 44,767,000,000 | 45,679,000,000 | 46,638,000,000 | 47,917,000,000 | 48,791,000,000 | 45,360,000,000 | 48,516,000,000 | 52,564,000,000 | 52,326,000,000 | 50,006,000,000 | 50,105,000,000 | 55,606,000,000 | 55,463,000,000 | 58,212,000,000 | 57,673,000,000 | 57,314,000,000 | 56,943,000,000 | 57,596,000,000 | 57,922,000,000 | 56,839,000,000 | 56,805,000,000 | 58,048,300,000 | 57,665,700,000 | 60,343,200,000 | 61,492,600,000 | ||||||||
property, plant and equipment | 11,012,000,000 | 10,785,000,000 | 10,244,000,000 | 10,554,000,000 | 10,918,000,000 | 10,792,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
land | 321,000,000 | 307,000,000 | 326,000,000 | 295,000,000 | 326,000,000 | 350,000,000 | 343,000,000 | 333,000,000 | 365,000,000 | 412,000,000 | 490,000,000 | 541,000,000 | 550,000,000 | 591,000,000 | 623,000,000 | 658,000,000 | 666,700,000 | 377,000,000 | 326,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
buildings | 17,983,000,000 | 16,360,000,000 | 14,966,000,000 | 13,166,000,000 | 12,529,000,000 | 12,645,000,000 | 11,989,000,000 | 11,486,000,000 | 11,726,000,000 | 11,439,000,000 | 12,154,000,000 | 13,101,000,000 | 13,627,000,000 | 13,196,000,000 | 12,733,000,000 | 11,945,000,000 | 12,210,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
machinery, equipment and office furnishings | 19,760,000,000 | 18,283,000,000 | 17,763,000,000 | 16,760,000,000 | 16,303,000,000 | 16,649,000,000 | 15,394,000,000 | 14,441,000,000 | 14,649,000,000 | 14,053,000,000 | 14,261,000,000 | 16,050,000,000 | 17,106,000,000 | 17,188,000,000 | 16,919,000,000 | 15,894,000,000 | 16,173,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
construction in progress | 9,166,000,000 | 7,984,000,000 | 8,262,000,000 | 9,186,000,000 | 8,313,000,000 | 7,324,000,000 | 5,013,000,000 | 3,355,000,000 | 2,301,000,000 | 1,871,000,000 | 1,525,000,000 | 1,448,000,000 | 1,811,000,000 | 2,440,000,000 | 2,198,000,000 | 2,066,000,000 | 1,817,500,000 | 1,008,000,000 | 891,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: accumulated depreciation | 21,914,000,000 | 19,155,000,000 | 18,266,000,000 | 17,985,000,000 | 18,192,000,000 | 18,982,000,000 | 17,686,000,000 | 16,324,000,000 | 16,602,000,000 | 15,749,000,000 | 15,923,000,000 | 18,004,000,000 | 18,121,000,000 | 17,385,000,000 | 16,176,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 1,102,476,756 shares in 2025 and 1,049,466,187 shares in 2024 | 62,999,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 20,605 in 2025 and 19,155 in 2024 | 25,639,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,089,754,712 shares in 2025 and 1,049,466,187 shares in 2024 | 61,799,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 20,256 in 2025 and 19,155 in 2024 | 25,236,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,073,963,194 shares in 2025 and 1,049,466,187 shares in 2024 | 60,495,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 19,680 in 2025 and 19,155 in 2024 | 24,793,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,061,021,894 shares in 2025 and 1,049,466,187 shares in 2024 | 59,401,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 1,049,466,187 shares in 2024 and 1,045,470,249 shares in 2023 | 58,303,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 19,072 in 2024 and 18,266 in 2023 | 23,446,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,045,073,377 shares in 2024 and 1,045,470,249 shares in 2023 | 57,829,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,960 in 2024 and 18,266 in 2023 | 23,221,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,041,454,052 shares in 2024 and 1,045,470,249 shares in 2023 | 57,394,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,620 in 2024 and 18,266 in 2023 | 23,045,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,044,402,655 shares in 2024 and 1,045,470,249 shares in 2023 | 57,445,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 1,045,470,249 shares in 2023 and 1,039,269,638 shares in 2022 | 57,450,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,446 in 2023 and 17,985 in 2022 | 22,526,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,041,809,729 shares in 2023 and 1,039,269,638 shares in 2022 | 57,066,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,432 in 2023 and 17,985 in 2022 | 22,231,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,037,678,033 shares in 2023 and 1,039,269,638 shares in 2022 | 56,612,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,256 in 2023 and 17,985 in 2022 | 21,758,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,039,651,210 shares in 2023 and 1,039,269,638 shares in 2022 | 56,577,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 1,039,269,638 shares in 2022 and 1,049,499,023 shares in 2021 | 56,489,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,921in 2022 and 18,192 in 2021 | 20,424,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021 | 56,758,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,798in 2022 and 18,192 in 2021 | 20,059,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,043,894,068 shares in 2022 and 1,049,499,023 shares in 2021 | 56,770,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,498in 2022 and 18,192 in 2021 | 19,747,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,048,727,225 shares in 2022 and 1,049,499,023 shares in 2021 | 57,063,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent assets of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent liabilities of discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 1,049,499,023 shares in 2021 and 1,046,877,695 shares in 2020 | 57,109,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,155in 2021 and 18,162 in 2020 | 18,565,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,051,780,149 shares in 2021 and 1,046,877,695 shares in 2020 | 57,244,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,236in 2021 and 18,162 in 2020 | 18,064,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,044,351,147 shares in 2021 and 1,046,877,695 shares in 2020 | 56,682,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,732in 2021 and 18,982 in 2020 | 18,295,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,045,799,775 shares in 2021 and 1,046,877,695 shares in 2020 | 56,722,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,046,877,695 shares in 2020 and 1,038,087,496 shares in 2019 | 56,787,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,572in 2020 and 17,686 in 2019 | 16,919,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,047,343,390 shares in 2020 and 1,038,087,496 shares in 2019 | 56,815,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,182in 2020 and 17,686 in 2019 | 15,789,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,047,935,095 shares in 2020 and 1,038,087,496 shares in 2019 | 56,850,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,706in 2020 and 17,686 in 2019 | 15,269,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,053,090,194 shares in 2020 and 1,038,087,496 shares in 2019 | 57,161,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,038,087,496 shares in 2019 and 984,543,979 shares in 2018 | 55,950,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,281in 2019 and 16,324 in 2018 | 14,287,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,026,214,892 shares in 2019 and 984,543,979 shares in 2018 | 54,925,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,049in 2019 and 16,324 in 2018 | 13,862,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:1,010,308,500 shares in 2019 and 984,543,979 shares in 2018 | 53,570,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,623in 2019 and 16,324 in 2018 | 13,506,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:994,032,308 shares in 2019 and 984,543,979 shares in 2018 | 51,736,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:984,543,979 shares in 2018 and 880,491,914 shares in 2017 | 50,929,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,568in 2018 and 16,602 in 2017 | 12,755,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:918,364,126 shares in 2018 and 880,491,914 shares in 2017 | 46,166,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,567in 2018 and 16,602 in 2017 | 12,626,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:907,061,576 shares in 2018 and 880,491,914 shares in 2017 | 45,401,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,483in 2018 and 16,602 in 2017 | 12,561,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:884,622,139 shares in 2018 and 880,491,914 shares in 2017 | 44,041,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:880,491,914 shares in 2017 and 828,372,200 shares in 2016 | 43,794,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,661in 2017 and 15,749 in 2016 | 12,189,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:850,698,697 shares in 2017 and 828,372,200 shares in 2016 | 42,119,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,375in 2017 and 15,749 in 2016 | 12,094,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:849,974,743 shares in 2017 and 828,372,200 shares in 2016 | 42,053,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,171in 2017 and 15,749 in 2016 | 12,042,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:836,667,641 shares in 2017 and 828,372,200 shares in 2016 | 41,157,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:828,372,200 shares in 2016 and 795,975,449 shares in 2015 | 40,546,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,022in 2016 and 15,923 in 2015 | 12,029,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:815,442,334 shares in 2016 and 795,975,449 shares in 2015 | 39,717,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,005in 2016 and 15,923 in 2015 | 11,987,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:811,476,036 shares in 2016 and 795,975,449 shares in 2015 | 39,377,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,052in 2016 and 15,923 in 2015 | 12,360,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:807,550,812 shares in 2016 and 795,975,449 shares in 2015 | 39,125,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:795,975,449 shares in 2015 and 738,963,326 shares in 2014 | 38,534,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes and other current assets | 4,941,000,000 | 5,133,000,000 | 5,117,000,000 | 5,257,000,000 | 4,740,000,000 | 3,659,000,000 | 3,939,000,000 | 4,789,000,000 | 5,277,000,000 | 4,352,000,000 | 4,484,000,000 | 4,509,000,000 | 3,429,000,000 | 3,788,000,000 | 3,713,000,000 | 3,694,000,000 | 4,158,000,000 | 3,687,000,000 | 3,983,000,000 | 3,651,000,000 | 3,570,100,000 | 3,790,700,000 | 4,144,500,000 | 4,165,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,043in 2015 and 18,004 in 2014 | 12,482,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:774,869,058 shares in 2015 and 738,963,326 shares in 2014 | 37,427,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,306in 2015 and 18,004 in 2014 | 12,630,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:753,147,765 shares in 2015 and 738,963,326 shares in 2014 | 36,225,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,794in 2015 and 18,004 in 2014 | 12,910,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:748,715,051 shares in 2015 and 738,963,326 shares in 2014 | 35,903,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:738,963,326 shares in 2014 and 649,576,808 shares in 2013 | 35,262,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
assets held for sale | 3,302,000,000 | 3,375,000,000 | 3,224,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,761in 2014 and 18,121 in 2013 | 13,438,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities held for sale | 810,000,000 | 801,000,000 | 848,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:716,260,636 shares in 2014 and 649,576,808 shares in 2013 | 33,895,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,866in 2014 and 18,121 in 2013 | 13,893,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:677,393,158 shares in 2014 and 649,576,808 shares in 2013 | 31,551,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 18,622in 2014 and 18,121 in 2013 | 14,296,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:647,565,088 shares in 2014 and 649,576,808 shares in 2013 | 29,745,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:649,576,808 shares in 2013 and 550,468,221 shares in 2012 | 29,591,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,805in 2013 and 17,385 in 2012 | 15,323,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes and noncurrent liabilities | 15,551,000,000 | 15,843,000,000 | 15,703,000,000 | 16,067,000,000 | 14,935,000,000 | 15,883,000,000 | 16,385,000,000 | 16,415,000,000 | 16,653,000,000 | 16,727,000,000 | 17,720,000,000 | 17,853,000,000 | 18,436,600,000 | 19,248,900,000 | 19,514,200,000 | 18,771,500,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:650,490,309 shares in 2013 and 550,468,221 shares in 2012 | 29,353,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,594in 2013 and 17,385 in 2012 | 15,683,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost:650,630,672 shares in 2013 and 550,468,221 shares in 2012 | 29,334,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,622 in 2013 and 17,385 in 2012 | 15,802,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: 559,727,953 shares in 2013 and 550,468,221 shares in 2012 | 25,129,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued — 3,577,103,522 shares in 2012 and 2011 | 1,788,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
550,468,221 shares in 2012; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
536,109,713 shares in 2011 | 24,717,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,475 in 2012 and 16,176 in 2011 | 15,884,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 6,500,000,000 shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,577,103,522 shares in 2012 and 2011 | 1,788,000,000 | 1,788,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
532,699,267 shares in 2012 and 536,109,713 shares in 2011 | 23,862,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 17,049 in 2012 and 16,176 in 2011 | 15,867,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
538,194,526 shares in 2012 and 536,109,713 shares in 2011 | 23,968,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 16,697 in 2012 and 16,176 in 2011 | 16,124,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,576,948,356 shares in 2012 and 2011 | 1,788,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
534,964,050 shares in 2012 and 536,109,713 shares in 2011 | 23,804,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued — 3,576,948,356 shares in 2011 and 2010 | 1,788,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
536,109,713 shares in 2011; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
494,841,533 shares in 2010 | 23,792,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 15,674 in 2011 and 13,481 in 2010 | 16,383,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,576,948,356 shares in 2011 and 2010 | 1,788,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost 525,000,622 shares in 2011 and 494,841,533 shares in 2010 | 23,415,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of accumulated depreciation of 15,195 in 2011 and 13,481 in 2010 | 16,671,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost 493,935,906 shares in 2011 and 494,841,533 shares in 2010 | 22,416,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of depreciation of 14,515 in 2011 and 13,481 in 2010 | 16,833,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost 491,657,062 shares in 2011 and 494,841,533 shares in 2010 | 22,324,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less allowance for depreciation | 13,481,000,000 | 12,594,600,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
6% mandatory convertible preferred stock, 1 par value | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized — 11,500,000 shares; issued and outstanding — 855,422 shares — 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized — 6,500,000,000 shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued — 3,576,948,356 shares — 2010; 3,562,528,536 — 2009 | 1,788,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
494,841,533 shares — 2010; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
454,305,985 shares — 2009 | 22,433,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of allowance for depreciation of 13,349.6 in 2010 and 12,594.7 in 2009 | 17,115,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized - 11,500,000 shares | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued and outstanding - 855,422 shares in 2009 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,576,948,356 shares in 2010; 3,562,528,536 shares in 2009 | 1,788,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury stock, at cost | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
497,029,750 shares in 2010 and 454,305,985 shares in 2009 | 22,507,800,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of allowance for depreciation of 12,819.8 in 2010 and 12,594.7 in 2009 | 17,334,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued and outstanding - 853,158 shares in 2010 and 855,422 shares in 2009 | 206,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,572,963,192 shares in 2010; 3,562,528,536 shares in 2009 | 1,786,500,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
491,662,773 shares in 2010 and 454,305,985 shares in 2009 | 22,315,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, plant and equipment, at cost, net of allowance for depreciation of 12,220.3 in 2010 and 12,594.7 in 2009 | 17,985,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued and outstanding - 853,896 shares in 2010 and 855,422 shares in 2009 | 206,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued - 3,571,947,847 shares in 2010; 3,562,528,536 shares in 2009 | 1,786,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
454,305,985 shares in 2010 and 2009 | 21,044,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventories (excludes inventories of 1,157.2 in 2009 and 587.3 in | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2008 classified in other assets — see note 8) | 8,055,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized — 11,500,000 shares; issued and outstanding — 855,422 shares | 206,600,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
authorized — 6,500,000,000 shares — 2009; 5,400,000,000 shares — 2008 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issued — 3,562,528,536 shares — 2009; 2,983,508,675 — 2008 | 1,781,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
454,305,985 shares — 2009; | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
875,818,333 shares — 2008 | 21,044,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current assets: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other current assets | 1,203,000,000 | 1,119,000,000 | 1,195,000,000 | 1,228,000,000 | 1,192,000,000 | 1,262,000,000 | 1,217,000,000 | 1,272,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less accumulated depreciation | 4,088,000,000 | 3,912,000,000 | 3,582,000,000 | 3,607,000,000 | 3,661,000,000 | 3,728,000,000 | 3,609,000,000 | 3,338,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property | 6,924,000,000 | 6,873,000,000 | 6,662,000,000 | 6,833,000,000 | 6,893,000,000 | 7,190,000,000 | 7,183,000,000 | 7,016,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other intangible assets | 5,981,000,000 | 5,947,000,000 | 5,761,000,000 | 6,154,000,000 | 6,416,000,000 | 7,098,000,000 | 7,271,000,000 | 7,004,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total assets | 30,547,000,000 | 29,545,000,000 | 27,718,000,000 | 28,117,000,000 | 28,491,000,000 | 30,121,000,000 | 30,120,000,000 | 29,156,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
liabilities and shareholders’ equity | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
current liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 1,709,000,000 | 1,755,000,000 | 1,670,000,000 | 1,677,000,000 | 1,723,000,000 | 1,787,000,000 | 1,912,000,000 | 1,762,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term borrowings and current portion of long-term debt | 185,000,000 | 261,000,000 | 204,000,000 | 245,000,000 | 237,000,000 | 456,000,000 | 487,000,000 | 461,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes | 232,000,000 | 202,000,000 | 162,000,000 | 183,000,000 | 463,000,000 | 464,000,000 | 455,000,000 | 617,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued compensation | 967,000,000 | 828,000,000 | 838,000,000 | 1,010,000,000 | 1,004,000,000 | 799,000,000 | 804,000,000 | 995,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other accrued liabilities | 1,996,000,000 | 2,148,000,000 | 2,087,000,000 | 2,078,000,000 | 1,989,000,000 | 2,252,000,000 | 2,165,000,000 | 2,208,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
long-term liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other long-term liabilities | 3,002,000,000 | 2,910,000,000 | 2,795,000,000 | 2,913,000,000 | 2,157,000,000 | 2,201,000,000 | 2,106,000,000 | 2,008,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total long-term liabilities | 12,558,000,000 | 12,316,000,000 | 11,922,000,000 | 12,395,000,000 | 11,956,000,000 | 13,009,000,000 | 13,264,000,000 | 12,728,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
commitments and contingent liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
shareholders’ equity: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at september 30, 2009 and december 31, 2008 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized: 2,400, .50 par value; issued: 2,132 at september 30, 2009 and 2,118 at december 31, 2008 | 1,066,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
paid-in capital | 5,340,000,000 | 5,196,000,000 | 5,128,000,000 | 5,045,000,000 | 4,996,000,000 | 4,933,000,000 | 4,877,000,000 | 4,815,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total | 18,283,000,000 | 17,418,000,000 | 16,178,000,000 | 10,440,000,000 | 16,462,000,000 | 16,696,000,000 | 16,341,000,000 | 10,354,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 493 at september 30, 2009 and 492 at december 31, 2008; at cost | 5,383,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total shareholders’ equity | 12,900,000,000 | 12,035,000,000 | 10,835,000,000 | 10,529,000,000 | 11,119,000,000 | 11,354,000,000 | 11,033,000,000 | 10,385,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
total liabilities and shareholders’ equity | 30,547,000,000 | 29,545,000,000 | 27,718,000,000 | 28,117,000,000 | 28,491,000,000 | 30,121,000,000 | 30,120,000,000 | 29,156,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at june 30, 2009 and december 31, 2008 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized: 2,400, .50 par value; issued: 2,127 at june 30, 2009 and 2,118 at december 31, 2008 | 1,064,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 493 at june 30, 2009 and 492 at december 31, 2008; at cost | 5,383,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at march 31, 2009 and december 31, 2008 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized: 2,400, .50 par value; issued: 2,120 at march 31, 2009 and 2,118 at december 31, 2008 | 1,060,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 492 at march 31, 2009 and december 31, 2008; at cost | 5,343,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable, less allowances | 2,816,000,000 | 2,841,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
property, at cost: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
buildings and improvements | 4,551,000,000 | 4,634,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equipment | 4,504,000,000 | 4,503,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value issued 10 at december 31, 2008 and december 31, 2007 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized shares: 2,400, .50 par value; issued: 2,118 at december 31, 2008 and 2,111 at december 31, 2007 | 1,059,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 2008, 492; 2007, 490; at cost | 5,343,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at september 30, 2008 and december 31, 2007 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized: 2,400, .50 par value; issued: 2,118 at september 30, 2008 and 2,111 at december 31, 2007 | 1,059,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 492 at september 30, 2008 and 490 at december 31, 2007; at cost | 5,343,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at june 30, 2008 and december 31, 2007 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized shares: 2,400, .50 par value; issued: 2,117 at june 30, 2008 and 2,111 at december 31, 2007 | 1,059,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 492 at june 30, 2008 and 490 at december 31, 2007; at cost | 5,342,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value; issued: 10 at march 31, 2008 and december 31, 2007 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized shares: 2,400, .50 par value; issued: 2,111 at march 31, 2008 and december 31, 2007 | 1,056,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 490 at march 31, 2008 and december 31, 2007; at cost | 5,308,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2004 mandatory convertible preferred shares — 1 par value; 50 per share face value; issued 0 at december 31, 2007 and 29 at december 31, 2006 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2007 mandatory convertible preferred shares — 1 par value; 250 per share face value issued 10 at december 31, 2007 and 0 at december 31, 2006 | 2,500,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
common shares — authorized shares: 2,400, .50 par value; issued: 2,111 at december 31, 2007 and 2,034 at december 31, 2006 | 1,055,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less treasury shares: 2007, 490; 2006, 547; at cost | 5,307,000,000 |
Cashflow Statements:
Quarterly
Annual
| Unit: USD | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 | 2015-12-31 | 2015-09-30 | 2015-06-30 | 2015-03-31 | 2014-12-31 | 2014-09-30 | 2014-06-30 | 2014-03-31 | 2013-12-31 | 2013-09-30 | 2013-06-30 | 2013-03-31 | 2012-12-31 | 2012-09-30 | 2012-06-30 | 2012-03-31 | 2011-12-31 | 2011-09-30 | 2011-06-30 | 2011-03-31 | 2010-12-31 | 2010-09-30 | 2010-06-30 | 2010-03-31 | 2009-03-31 | 2008-12-31 | 2008-09-30 | 2008-06-30 | 2008-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash flows from operating activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income | -4,243,000,000 | 2,962,000,000 | 5,787,000,000 | 4,429,000,000 | 5,085,000,000 | 3,744,000,000 | 3,161,000,000 | 5,461,000,000 | 4,767,000,000 | 4,750,000,000 | -5,972,000,000 | 2,825,000,000 | 3,186,000,000 | -2,091,000,000 | 2,944,000,000 | 3,010,000,000 | 3,219,000,000 | 2,363,000,000 | 1,908,000,000 | 2,644,000,000 | 2,862,000,000 | 1,778,000,000 | 1,958,000,000 | 1,716,000,000 | 741,000,000 | -1,038,000,000 | -51,000,000 | 1,951,000,000 | 1,556,000,000 | -587,000,000 | 2,189,000,000 | 1,209,000,000 | 1,130,000,000 | 982,000,000 | 1,831,000,000 | 688,000,000 | 958,000,000 | 7,327,000,000 | 843,000,000 | 2,033,000,000 | 1,731,000,000 | 815,000,000 | 1,151,000,000 | 935,000,000 | 1,616,000,000 | 949,000,000 | 1,763,000,000 | 1,820,000,000 | 1,767,000,000 | 1,543,000,000 | 1,724,000,000 | 2,054,000,000 | 1,071,000,000 | -500,000,000 | 371,600,000 | 780,200,000 | 330,200,000 | 805,000,000 | 588,000,000 | 589,000,000 | 435,000,000 | 291,000,000 | ||||||||
adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
amortization | 931,000,000 | 973,000,000 | 622,000,000 | 601,000,000 | 597,000,000 | 675,000,000 | 633,000,000 | 614,000,000 | 473,000,000 | 462,000,000 | 562,000,000 | 477,000,000 | 543,000,000 | 462,000,000 | 460,000,000 | 464,000,000 | 699,000,000 | 405,000,000 | 360,000,000 | 337,000,000 | 534,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
depreciation | 581,000,000 | 1,493,000,000 | 532,000,000 | 518,000,000 | 502,000,000 | 522,000,000 | 553,000,000 | 518,000,000 | 511,000,000 | 502,000,000 | 452,000,000 | 426,000,000 | 448,000,000 | 430,000,000 | 499,000,000 | 474,000,000 | 421,000,000 | 430,000,000 | 399,000,000 | 353,000,000 | 396,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||
income from investments in equity securities | -168,000,000 | 195,000,000 | -374,000,000 | -99,000,000 | -90,000,000 | 31,000,000 | -57,000,000 | -143,000,000 | -405,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for research and development asset acquisition | 8,540,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
deferred income taxes | -315,000,000 | -825,000,000 | -212,000,000 | -448,000,000 | -186,000,000 | -616,000,000 | -401,000,000 | -181,000,000 | -51,000,000 | -931,000,000 | -336,000,000 | -355,000,000 | -277,000,000 | -307,000,000 | -661,000,000 | -262,000,000 | -338,000,000 | 159,000,000 | -1,000,000 | 39,000,000 | -10,000,000 | -715,000,000 | -75,000,000 | 40,000,000 | 82,000,000 | -170,000,000 | -237,000,000 | -343,000,000 | 194,000,000 | -118,000,000 | -133,000,000 | -228,000,000 | -30,000,000 | -2,020,000,000 | -329,000,000 | -218,000,000 | -54,000,000 | -1,456,000,000 | 55,000,000 | -50,000,000 | -70,000,000 | 82,000,000 | -463,000,000 | -204,000,000 | -179,000,000 | -827,000,000 | -527,000,000 | -942,000,000 | -304,000,000 | 202,000,000 | -213,000,000 | -248,000,000 | -71,000,000 | 952,000,000 | 82,000,000 | -563,000,000 | -133,000,000 | -627,000,000 | -214,000,000 | -349,200,000 | -423,900,000 | -471,100,000 | 152,200,000 | |||||||
share-based compensation | 185,000,000 | 205,000,000 | 204,000,000 | 216,000,000 | 195,000,000 | 187,000,000 | 195,000,000 | 203,000,000 | 176,000,000 | 167,000,000 | 164,000,000 | 169,000,000 | 145,000,000 | 145,000,000 | 139,000,000 | 137,000,000 | 120,000,000 | 119,000,000 | 117,000,000 | 123,000,000 | 120,000,000 | 121,000,000 | 125,000,000 | 121,000,000 | 108,000,000 | 111,000,000 | 102,000,000 | 111,000,000 | 93,000,000 | 87,000,000 | 91,000,000 | 90,000,000 | 80,000,000 | 80,000,000 | 76,000,000 | 82,000,000 | 74,000,000 | 75,000,000 | 77,000,000 | 80,000,000 | 68,000,000 | 78,000,000 | 75,000,000 | 83,000,000 | 63,000,000 | 69,000,000 | 75,000,000 | 78,000,000 | 56,000,000 | 66,000,000 | 68,000,000 | 75,000,000 | 67,000,000 | 78,000,000 | 88,000,000 | 93,000,000 | 76,000,000 | 82,000,000 | 87,000,000 | 107,000,000 | 93,000,000 | 109,500,000 | 125,300,000 | 141,800,000 | 132,400,000 | |||||
other | 20,000,000 | 118,000,000 | -51,000,000 | 335,000,000 | 109,000,000 | -101,000,000 | 437,000,000 | 91,000,000 | 83,000,000 | 449,000,000 | -99,000,000 | 202,000,000 | -197,000,000 | 132,000,000 | 393,000,000 | 633,000,000 | 143,000,000 | 306,000,000 | 1,025,000,000 | -195,000,000 | -331,000,000 | 396,000,000 | -243,000,000 | -345,000,000 | 143,000,000 | -35,000,000 | 105,000,000 | -6,000,000 | 120,000,000 | 393,000,000 | 156,000,000 | 379,000,000 | 50,000,000 | 300,000,000 | -94,000,000 | 91,000,000 | -28,000,000 | 66,000,000 | 50,000,000 | 100,000,000 | 97,000,000 | 60,000,000 | 120,000,000 | 26,000,000 | 551,000,000 | -45,000,000 | 142,000,000 | -77,000,000 | -115,000,000 | 112,000,000 | -85,000,000 | 46,000,000 | 326,000,000 | 62,000,000 | -177,000,000 | 72,000,000 | 71,000,000 | 530,000,000 | 249,000,000 | -234,000,000 | -222,000,000 | -66,600,000 | 6,600,000 | 249,000,000 | 188,000,000 | 2,000,000 | ||||
net changes in assets and liabilities | -1,613,000,000 | 1,314,000,000 | -2,259,000,000 | -3,712,000,000 | 2,582,000,000 | -1,012,000,000 | -3,382,000,000 | 2,177,000,000 | -1,636,000,000 | -2,890,000,000 | 263,000,000 | -1,399,000,000 | -1,299,000,000 | -139,000,000 | -1,551,000,000 | -2,104,000,000 | -1,445,000,000 | -527,000,000 | -3,666,000,000 | -91,000,000 | -443,000,000 | -2,935,000,000 | -760,000,000 | 199,000,000 | -1,473,000,000 | -2,922,000,000 | 198,000,000 | -2,535,000,000 | -564,000,000 | -1,563,000,000 | -875,000,000 | 223,000,000 | -392,000,000 | -618,000,000 | 2,068,000,000 | -415,000,000 | -703,000,000 | 1,315,000,000 | -636,000,000 | -1,173,000,000 | -282,000,000 | 821,000,000 | -418,000,000 | -1,067,000,000 | 787,100,000 | 1,058,500,000 | -1,064,000,000 | |||||||||||||||||||||||
net cash from operating activities | 3,918,000,000 | 2,857,000,000 | 7,822,000,000 | 3,293,000,000 | 2,500,000,000 | 3,450,000,000 | 9,291,000,000 | 5,637,000,000 | 3,090,000,000 | 7,717,000,000 | 3,704,000,000 | 1,339,000,000 | -64,000,000 | 0 | -740,000,000 | 1,791,000,000 | 4,006,000,000 | 2,173,000,000 | 3,367,000,000 | 707,000,000 | 4,794,000,000 | 4,226,000,000 | 3,084,000,000 | 1,336,000,000 | 3,592,000,000 | 2,793,000,000 | 3,382,000,000 | 1,155,000,000 | 4,015,000,000 | -1,171,000,000 | 3,317,000,000 | 286,000,000 | 3,632,000,000 | 2,971,000,000 | 1,615,000,000 | 2,158,000,000 | 4,247,000,000 | 3,305,000,000 | 2,585,000,000 | 2,284,000,000 | -1,164,000,000 | 4,348,000,000 | 2,315,000,000 | 2,361,000,000 | 3,026,000,000 | 3,949,000,000 | 2,338,000,000 | 2,341,000,000 | 1,809,000,000 | 3,139,000,000 | 2,920,000,000 | 2,154,000,000 | 3,233,000,000 | 4,577,000,000 | 2,852,000,000 | 1,721,000,000 | 3,539,100,000 | 2,591,900,000 | 3,324,900,000 | 1,366,100,000 | 556,000,000 | 789,000,000 | 1,191,000,000 | |||||||
cash flows from investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
capital expenditures | -991,000,000 | -1,033,000,000 | -987,000,000 | -764,000,000 | -1,328,000,000 | -937,000,000 | -783,000,000 | -791,000,000 | -861,000,000 | -902,000,000 | -965,000,000 | -1,007,000,000 | -1,208,000,000 | -1,172,000,000 | -934,000,000 | -1,134,000,000 | -1,514,000,000 | -1,516,000,000 | -668,000,000 | -986,000,000 | -1,137,000,000 | -959,000,000 | -782,000,000 | -595,000,000 | -929,000,000 | -653,000,000 | -583,000,000 | -450,000,000 | -715,000,000 | -441,000,000 | -393,000,000 | -339,000,000 | -551,000,000 | -409,000,000 | -375,000,000 | -279,000,000 | -493,000,000 | -316,000,000 | -271,000,000 | -203,000,000 | -490,000,000 | -320,000,000 | -302,000,000 | -205,000,000 | -429,000,000 | -355,000,000 | -413,000,000 | -351,000,000 | -778,000,000 | -414,000,000 | 0 | 0 | -603,000,000 | -431,000,000 | -365,000,000 | -324,000,000 | -660,300,000 | -337,900,000 | -337,000,000 | -342,800,000 | -161,000,000 | -205,000,000 | -172,000,000 | |||||||
free cash flows | 2,927,000,000 | 1,824,000,000 | 6,835,000,000 | 2,529,000,000 | 1,172,000,000 | 2,513,000,000 | 8,508,000,000 | 4,846,000,000 | 2,229,000,000 | 6,815,000,000 | 2,739,000,000 | 332,000,000 | -1,272,000,000 | -1,172,000,000 | -1,674,000,000 | 657,000,000 | 2,492,000,000 | 657,000,000 | 2,699,000,000 | -279,000,000 | 3,657,000,000 | 3,267,000,000 | 2,302,000,000 | 741,000,000 | 2,663,000,000 | 2,140,000,000 | 2,799,000,000 | 705,000,000 | 3,300,000,000 | -1,612,000,000 | 2,924,000,000 | -53,000,000 | 3,081,000,000 | 2,562,000,000 | 1,240,000,000 | 1,879,000,000 | 3,754,000,000 | 2,989,000,000 | 2,314,000,000 | 2,081,000,000 | -1,654,000,000 | 4,028,000,000 | 2,013,000,000 | 2,156,000,000 | 2,597,000,000 | 3,594,000,000 | 1,925,000,000 | 1,990,000,000 | 1,031,000,000 | 2,725,000,000 | 2,920,000,000 | 2,154,000,000 | 2,630,000,000 | 4,146,000,000 | 2,487,000,000 | 1,397,000,000 | 2,878,800,000 | 2,254,000,000 | 2,987,900,000 | 1,023,300,000 | 395,000,000 | 584,000,000 | 1,019,000,000 | |||||||
purchases of securities and other investments | -374,000,000 | 0 | 0 | -612,000,000 | -595,000,000 | -455,000,000 | 0 | -49,000,000 | -15,000,000 | -251,000,000 | -117,000,000 | -25,000,000 | -562,000,000 | -494,000,000 | -5,000,000 | -333,000,000 | -372,000,000 | 0 | 0 | 0 | -1,000,000 | -17,000,000 | -1,000,000 | -28,000,000 | -49,000,000 | -822,000,000 | -570,000,000 | -836,000,000 | -974,000,000 | -1,095,000,000 | -1,651,000,000 | -3,922,000,000 | -1,326,000,000 | -2,342,000,000 | -2,117,000,000 | -3,351,000,000 | -2,929,000,000 | -5,567,000,000 | -3,729,000,000 | -3,988,000,000 | -2,367,000,000 | -4,256,000,000 | -3,804,000,000 | -3,582,000,000 | -5,039,000,000 | -8,713,000,000 | -3,851,000,000 | -5,555,000,000 | -6,825,000,000 | -4,914,000,000 | -4,259,000,000 | -4,808,000,000 | -4,010,000,000 | -5,950,000,000 | -2,890,000,000 | -2,639,000,000 | -1,620,000,000 | -1,684,000,000 | -1,382,000,000 | -1,370,900,000 | -1,590,900,000 | -1,302,500,000 | -2,932,700,000 | |||||||
proceeds from sales of securities and other investments | 46,000,000 | 575,000,000 | 601,000,000 | 456,000,000 | 7,000,000 | 50,000,000 | 60,000,000 | 260,000,000 | 169,000,000 | 704,000,000 | 285,000,000 | 500,000,000 | 12,000,000 | 335,000,000 | 373,000,000 | 1,000,000 | 529,000,000 | 111,000,000 | 0 | 386,000,000 | 918,000,000 | 2,000,000 | 76,000,000 | 1,816,000,000 | 1,163,000,000 | 2,524,000,000 | 3,036,000,000 | 1,899,000,000 | 4,009,000,000 | 3,840,000,000 | 5,555,000,000 | 1,848,000,000 | 3,131,000,000 | 3,170,000,000 | 2,544,000,000 | 6,819,000,000 | 3,053,000,000 | 3,912,000,000 | 2,768,000,000 | 4,620,000,000 | 3,882,000,000 | 3,903,000,000 | 6,341,000,000 | 6,287,000,000 | 3,307,000,000 | 3,705,000,000 | 5,470,000,000 | 2,632,000,000 | 6,475,000,000 | 2,628,000,000 | 4,034,000,000 | 3,161,000,000 | 2,176,000,000 | 1,433,000,000 | 1,377,000,000 | 2,797,000,000 | 1,409,000,000 | 1,850,000,000 | 1,366,000,000 | 1,524,000,000 | 834,700,000 | 2,026,700,000 | 1,426,900,000 | 272,700,000 | ||||||
acquisition of cidara therapeutics, inc., net of cash acquired | -8,779,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities | -10,210,000,000 | -11,201,000,000 | -283,000,000 | -770,000,000 | -1,487,000,000 | -1,444,000,000 | -3,845,000,000 | -1,069,000,000 | -1,376,000,000 | -334,000,000 | -11,443,000,000 | -2,359,000,000 | 0 | 0 | 604,000,000 | -738,000,000 | -4,778,000,000 | -2,155,000,000 | -882,000,000 | -1,628,000,000 | -763,000,000 | 191,000,000 | -2,425,000,000 | 368,000,000 | 2,178,000,000 | 1,660,000,000 | 673,000,000 | -197,000,000 | -58,000,000 | 671,000,000 | -1,127,000,000 | 3,193,000,000 | -2,563,000,000 | -890,000,000 | -1,498,000,000 | 1,741,000,000 | -617,000,000 | -61,000,000 | 2,525,000,000 | -6,605,000,000 | 7,204,000,000 | -3,722,000,000 | -49,000,000 | -3,807,000,000 | 1,177,000,000 | -2,037,000,000 | -1,135,000,000 | -1,153,000,000 | -4,398,000,000 | -1,839,000,000 | -1,684,000,000 | -263,000,000 | -1,048,000,000 | 105,000,000 | -1,007,500,000 | 194,800,000 | -861,000,000 | |||||||||||||
cash flows from financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net change in short-term borrowings | 1,061,000,000 | 15,000,000 | -3,000,000 | 0 | -4,771,000,000 | 788,000,000 | 2,860,000,000 | -2,278,000,000 | -1,616,000,000 | 3,583,000,000 | 182,000,000 | -360,000,000 | 603,000,000 | -4,135,000,000 | 2,830,000,000 | 225,000,000 | 2,070,000,000 | -1,000,000 | -1,988,000,000 | 1,986,000,000 | -3,808,000,000 | 3,784,000,000 | 918,000,000 | -14,000,000 | 3,000,000 | -3,706,000,000 | 2,177,000,000 | -3,537,000,000 | 4,963,000,000 | -5,035,000,000 | 3,149,000,000 | -310,000,000 | -1,551,000,000 | 822,000,000 | 880,000,000 | 904,000,000 | -1,917,000,000 | 1,003,000,000 | 634,000,000 | -280,000,000 | -40,000,000 | 1,593,000,000 | -197,000,000 | -1,483,000,000 | -84,700,000 | -962,700,000 | 2,620,400,000 | -2,000,000 | -167,000,000 | -4,000,000 | -36,000,000 | |||||||||||||||||||
payments on debt | -1,140,000,000 | -2,000,000 | -1,000,000 | 0 | -2,500,000,000 | -539,000,000 | 0 | 0 | -751,000,000 | -3,000,000 | -1,000,000 | -1,750,000,000 | -1,000,000 | -1,000,000 | -1,000,000,000 | 0 | -1,250,000,000 | -1,166,000,000 | 0 | 0 | -1,153,000,000 | -3,000,000 | -2,000,000 | -1,000,000 | -1,951,000,000 | -1,280,000,000 | 1,000,000 | -2,005,000,000 | -1,003,000,000 | -802,000,000 | 0 | -1,000,000 | -300,000,000 | 0 | -35,000,000 | -1,500,000,000 | -851,000,000 | -1,000,000 | 0 | -3,000,000 | -2,902,000,000 | -6,610,000,000 | -2,000,000 | -2,000,000 | -3,000,000 | -1,260,000,000 | 0 | -9,000,000 | -506,000,000 | -270,000,000 | -12,000,000 | -1,261,000,000 | -4,000,000 | -651,700,000 | -63,200,000 | -3,800,000 | -622,300,000 | |||||||||||||
dividends paid to stockholders | -2,105,000,000 | -2,018,000,000 | -2,031,000,000 | -2,077,000,000 | -2,050,000,000 | -1,951,000,000 | -1,953,000,000 | -1,986,000,000 | -1,950,000,000 | -1,852,000,000 | -1,855,000,000 | -1,885,000,000 | -1,853,000,000 | -1,750,000,000 | -1,747,000,000 | -1,770,000,000 | -1,745,000,000 | -1,643,000,000 | -1,649,000,000 | -1,673,000,000 | -1,645,000,000 | -1,542,000,000 | -1,545,000,000 | -1,577,000,000 | -1,551,000,000 | -1,405,000,000 | -1,394,000,000 | -1,468,000,000 | -1,428,000,000 | -1,277,000,000 | -1,285,000,000 | -1,311,000,000 | -1,299,000,000 | -1,283,000,000 | -1,283,000,000 | -1,307,000,000 | -1,294,000,000 | -1,271,000,000 | -1,274,000,000 | -1,300,000,000 | -1,279,000,000 | -1,263,000,000 | -1,272,000,000 | -1,302,000,000 | -1,280,000,000 | -1,259,000,000 | -1,282,000,000 | -1,339,000,000 | -1,290,000,000 | -1,260,000,000 | -1,259,000,000 | -1,332,000,000 | -1,306,000,000 | -1,280,000,000 | -1,277,000,000 | -1,165,000,000 | -1,175,000,000 | -1,176,000,000 | -1,175,000,000 | -1,174,800,000 | -1,181,300,000 | -1,189,300,000 | -1,188,600,000 | |||||||
purchases of treasury stock | -874,000,000 | -1,252,000,000 | -1,323,000,000 | -1,345,000,000 | -1,164,000,000 | -489,000,000 | -444,000,000 | -251,000,000 | -122,000,000 | -393,000,000 | -466,000,000 | -338,000,000 | -149,000,000 | -18,000,000 | -583,000,000 | 0 | 0 | 0 | -1,281,000,000 | -1,050,000,000 | -1,405,000,000 | -1,235,000,000 | -1,090,000,000 | -5,933,000,000 | -996,000,000 | -1,596,000,000 | -566,000,000 | -1,702,000,000 | -159,000,000 | -1,134,000,000 | -1,019,000,000 | -1,016,000,000 | -845,000,000 | -660,000,000 | -913,000,000 | -1,181,000,000 | -1,281,000,000 | -709,000,000 | -1,015,000,000 | -1,620,000,000 | -2,670,000,000 | -2,246,000,000 | -1,167,000,000 | -196,000,000 | -215,000,000 | -5,525,000,000 | -580,000,000 | -1,152,000,000 | -454,000,000 | -562,000,000 | -1,045,000,000 | 300,000 | -296,100,000 | |||||||||||||||||
proceeds from exercise of stock options | 157,000,000 | 47,000,000 | 14,000,000 | 12,000,000 | 19,000,000 | 12,000,000 | 5,000,000 | 73,000,000 | 87,000,000 | 6,000,000 | 7,000,000 | 82,000,000 | 30,000,000 | 265,000,000 | 10,000,000 | 97,000,000 | 12,000,000 | 134,000,000 | 17,000,000 | 42,000,000 | 9,000,000 | 21,000,000 | 28,000,000 | 14,000,000 | 26,000,000 | 17,000,000 | 40,000,000 | 131,000,000 | 173,000,000 | 130,000,000 | 162,000,000 | 69,000,000 | 230,000,000 | 18,000,000 | 73,000,000 | 95,000,000 | 313,000,000 | 149,000,000 | 409,000,000 | 179,000,000 | 202,000,000 | 51,000,000 | 57,000,000 | 135,000,000 | 242,000,000 | 179,000,000 | 247,000,000 | 203,000,000 | 931,000,000 | 401,000,000 | 168,000,000 | 549,000,000 | 92,000,000 | 250,000,000 | 459,000,000 | 222,000,000 | 379,000,000 | 127,000,000 | 32,000,000 | 125,000,000 | 37,000,000 | 50,100,000 | 75,700,000 | 41,900,000 | 195,300,000 | |||||
net cash from financing activities | -2,981,000,000 | 4,751,000,000 | 2,638,000,000 | -3,556,000,000 | -5,755,000,000 | -3,009,000,000 | -2,425,000,000 | 1,216,000,000 | -2,814,000,000 | -4,269,000,000 | 3,758,000,000 | -2,054,000,000 | 0 | 0 | 1,594,000,000 | -2,098,000,000 | 1,372,000,000 | -3,851,000,000 | 1,137,000,000 | -1,490,000,000 | -2,011,000,000 | -3,152,000,000 | -2,084,000,000 | -1,614,000,000 | -5,566,000,000 | -1,905,000,000 | -2,967,000,000 | -2,722,000,000 | -5,785,000,000 | 536,000,000 | -6,218,000,000 | 1,461,000,000 | -1,977,000,000 | -835,000,000 | -3,381,000,000 | -2,851,000,000 | -2,407,000,000 | -2,533,000,000 | -5,485,000,000 | 5,155,000,000 | -9,643,000,000 | 1,279,000,000 | -8,369,000,000 | 1,620,000,000 | -2,624,000,000 | -2,915,000,000 | 970,000,000 | -1,421,000,000 | -1,218,000,000 | -738,000,000 | -2,231,000,000 | -2,244,000,000 | -1,257,000,000 | -1,172,000,000 | -1,294,900,000 | -1,625,000,000 | -181,000,000 | -465,000,000 | -184,000,000 | |||||||||||
effect of exchange rate changes on cash, cash equivalents and restricted cash | -19,000,000 | 23,000,000 | 10,000,000 | 374,000,000 | 156,000,000 | -367,000,000 | 294,000,000 | -82,000,000 | -138,000,000 | 186,000,000 | -157,000,000 | -93,000,000 | 87,000,000 | 366,000,000 | -412,000,000 | -309,000,000 | -55,000,000 | -68,000,000 | -46,000,000 | 78,000,000 | -97,000,000 | 164,000,000 | 87,000,000 | 65,000,000 | -63,000,000 | 43,000,000 | -54,000,000 | 8,000,000 | 20,000,000 | -65,000,000 | -32,000,000 | -262,000,000 | 154,000,000 | |||||||||||||||||||||||||||||||||||||
net decrease in cash, cash equivalents and restricted cash | -9,292,000,000 | -4,586,000,000 | -1,238,000,000 | -1,142,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at beginning of year | 14,690,000,000 | 0 | 0 | 0 | 13,318,000,000 | 0 | 0 | 0 | 6,909,000,000 | 0 | 0 | 0 | 12,773,000,000 | 0 | 0 | 0 | 8,167,000,000 | 0 | 0 | -12,000,000 | 8,165,000,000 | 0 | 0 | 0 | 9,934,000,000 | 0 | 0 | 0 | 7,967,000,000 | 0 | 0 | 0 | 6,096,000,000 | |||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of period | 5,398,000,000 | 10,187,000,000 | -659,000,000 | 8,732,000,000 | 3,315,000,000 | 5,702,000,000 | 5,671,000,000 | 2,957,000,000 | -4,074,000,000 | 9,786,000,000 | 1,526,000,000 | 1,139,000,000 | 8,614,000,000 | 1,416,000,000 | 1,607,000,000 | 7,023,000,000 | -3,746,000,000 | 3,687,000,000 | 7,460,000,000 | 1,211,000,000 | -1,417,000,000 | 8,077,000,000 | 2,516,000,000 | 826,000,000 | 4,486,000,000 | |||||||||||||||||||||||||||||||||||||||||||||
intangible asset impairment charges | 779,000,000 | 839,000,000 | 887,000,000 | 1,683,000,000 | 15,000,000 | 176,000,000 | 612,000,000 | 148,000,000 | 104,000,000 | 270,000,000 | 245,000,000 | 51,000,000 | 80,000,000 | 3,376,000,000 | 5,000,000 | 290,000,000 | 277,000,000 | 82,000,000 | 7,000,000 | 59,000,000 | 14,000,000 | 13,000,000 | 549,000,000 | 171,000,000 | 0 | 564,000,000 | 30,000,000 | 24,000,000 | 40,000,000 | 127,000,000 | 9,000,000 | 244,000,000 | 22,000,000 | |||||||||||||||||||||||||||||||||||||
charges for certain research and development asset acquisitions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net changes in assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts receivable | -292,000,000 | 49,000,000 | 275,000,000 | -24,000,000 | -383,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
inventories | -239,000,000 | -127,000,000 | -23,000,000 | 26,000,000 | -138,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
trade accounts payable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued and other current liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
income taxes payable | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
noncurrent liabilities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of seagen inc. common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of verona pharma plc, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of eyebiotech limited, net of cash acquired | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of elanco animal health incorporated aqua business | -2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of harpoon therapeutics, inc., net of cash acquired | 0 | 0 | 0 | -746,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of mk-1045 from curon pharmaceutical | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of prometheus biosciences, inc., net of cash acquired | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of imago biosciences inc., net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from issuance of debt | 7,918,000,000 | 0 | -1,000,000 | 0 | -7,000,000 | 0 | -26,000,000 | 0 | 0 | 0 | 4,958,000,000 | 1,071,000,000 | 0 | 0 | -2,000,000 | -1,000,000 | 7,941,000,000 | 3,145,000,000 | 0 | 0 | 0 | 58,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
net increase in cash, cash equivalents and restricted cash | -3,570,000,000 | 10,187,000,000 | -1,370,000,000 | 3,315,000,000 | -1,760,000,000 | 2,957,000,000 | -4,074,000,000 | -2,987,000,000 | 1,494,000,000 | 1,526,000,000 | 1,139,000,000 | 447,000,000 | -1,879,000,000 | 1,416,000,000 | 3,687,000,000 | -2,474,000,000 | 2,063,000,000 | 110,000,000 | 139,000,000 | 2,516,000,000 | 826,000,000 | -1,610,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||
cash, cash equivalents and restricted cash at end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charges for research and development asset acquisitions | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of mk-1045 (formerly cn201) from curon pharmaceutical | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss from investments in equity securities | -100,000,000 | 34,000,000 | 176,000,000 | -450,000,000 | 58,000,000 | 370,000,000 | 283,000,000 | 708,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of eyebiotech limited | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of mk-1045 (formerly cn201) from curon pharmaceutical | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of harpoon therapeutics, inc. | 0 | 0 | 656,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of prometheus biosciences, inc. | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of imago biosciences, inc. | 0 | 0 | 0 | 1,192,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of imago biosciences, inc., net of cash acquired | 0 | 0 | -1,327,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from operating activities of continuing operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income from continuing operations | 3,018,000,000 | 3,252,000,000 | 3,949,000,000 | 4,307,000,000 | 3,824,000,000 | 4,571,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income from continuing operations to net cash from operating activities of continuing operations: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of pandion therapeutics, inc. | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities of continuing operations | 4,430,000,000 | 5,602,000,000 | 4,302,000,000 | 4,761,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from investing activities of continuing operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of acceleron pharma inc., net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of pandion therapeutics, inc., net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other acquisitions, net of cash acquired | 0 | -90,000,000 | 1,000,000 | -76,000,000 | -14,000,000 | -458,000,000 | -586,000,000 | -25,000,000 | 1,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities of continuing operations | -1,748,000,000 | -962,000,000 | -1,077,000,000 | -1,173,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from financing activities of continuing operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distribution from organon & co. | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities of continuing operations | -1,554,000,000 | -2,702,000,000 | -1,777,000,000 | -3,086,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash flows from discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash flows from discontinued operations | -64,000,000 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of velosbio inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of seagen inc. common stock | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of velosbio inc., net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of arqule, inc., net of cash acquired | 0 | 0 | 0 | -2,545,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
less: cash and cash equivalents related to discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for the acquisition of peloton therapeutics, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of antelliq corporation, net of cash acquired | 0 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of peloton therapeutics, inc., net of cash acquired | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
discontinued operations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income from continuing operations to net cash from operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from operating activities from continuing operations | 4,797,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of pandion therapeutics, inc. net of cash acquired | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from investing activities from continuing operations | -1,061,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from financing activities from continuing operations | -2,274,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for future payments related to collaboration license options | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
depreciation and amortization | 852,000,000 | 1,048,000,000 | 821,000,000 | 936,000,000 | 845,000,000 | 973,000,000 | 898,000,000 | 1,095,000,000 | 1,061,000,000 | 1,226,000,000 | 1,137,000,000 | 1,128,000,000 | 1,154,000,000 | 1,162,000,000 | 1,193,000,000 | 1,155,000,000 | 1,175,000,000 | 1,550,000,000 | 1,561,000,000 | 1,560,000,000 | 1,570,000,000 | 1,608,000,000 | 1,637,000,000 | 1,573,000,000 | 1,611,000,000 | 1,753,000,000 | 1,754,000,000 | 1,954,000,000 | 1,705,000,000 | 1,655,000,000 | 1,674,000,000 | 1,661,000,000 | 1,723,000,000 | 1,804,000,000 | 1,790,000,000 | 1,861,000,000 | 1,903,000,000 | 1,832,000,000 | 1,831,000,000 | 1,866,000,000 | 1,879,900,000 | 1,947,700,000 | 1,687,400,000 | 296,000,000 | 362,000,000 | 394,000,000 | 543,000,000 | 876,000,000 | ||||||||||||||||||||||
charge for acquisition of peloton therapeutics, inc. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
provisional charge for one-time transition tax related to the enactment of u.s. tax legislation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for collaboration termination | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge related to the settlement of worldwide keytruda patent litigation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions, net of cash acquired | -59,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for future payments related to eisai collaboration license options | 0 | 650,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of businesses, net of cash acquired | 0 | -41,000,000 | -306,000,000 | 0 | 0 | -104,200,000 | -10,500,000 | -10,000,000 | -131,300,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
charge for future payments related to astrazeneca collaboration license options | -250,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign currency devaluation related to venezuela | 161,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net charge related to the settlement of vioxx shareholder class action litigation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
equity income from affiliates | -27,000,000 | -21,000,000 | -4,000,000 | -34,000,000 | 5,000,000 | -63,000,000 | -2,000,000 | -145,000,000 | -16,000,000 | -24,000,000 | -93,000,000 | -124,000,000 | -53,000,000 | -102,000,000 | -116,000,000 | -133,000,000 | -232,000,000 | -157,000,000 | -256,000,000 | -161,000,000 | -55,000,000 | -138,000,000 | -170,200,000 | -236,400,000 | -42,900,000 | -137,500,000 | ||||||||||||||||||||||||||||||||||||||||||||
dividends and distributions from equity method affiliates | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of cubist pharmaceuticals, inc., net of cash acquired | 0 | 0 | 0 | -7,598,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisitions of other businesses, net of cash acquired | -2,000,000 | -621,000,000 | -10,000,000 | -147,000,000 | -36,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dispositions of businesses, net of cash divested | 126,000,000 | 490,000,000 | 25,000,000 | 533,000,000 | 0 | 0 | 17,000,000 | 306,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rate changes on cash and cash equivalents | 19,000,000 | 79,000,000 | 106,000,000 | 253,000,000 | -484,000,000 | 53,000,000 | 156,000,000 | 144,000,000 | -247,000,000 | -85,000,000 | -683,000,000 | -295,000,000 | -326,000,000 | -278,000,000 | 18,000,000 | 33,000,000 | -48,000,000 | 3,000,000 | -107,000,000 | -194,000,000 | -102,000,000 | 46,000,000 | -40,000,000 | -159,000,000 | 100,000,000 | 141,000,000 | -210,700,000 | 47,100,000 | 104,200,000 | -235,600,000 | ||||||||||||||||||||||||||||||||||||||||
net increase in cash and cash equivalents | -1,809,000,000 | 115,000,000 | -3,922,000,000 | 5,193,000,000 | -1,392,000,000 | 1,192,000,000 | 976,000,000 | 539,000,000 | -3,929,000,000 | 1,627,000,000 | -6,085,000,000 | 207,000,000 | 1,531,000,000 | -1,000,000,000 | 2,066,000,000 | -427,000,000 | -3,909,000,000 | 608,000,000 | 2,096,000,000 | 1,125,000,000 | -722,000,000 | 1,911,000,000 | 647,000,000 | 795,000,000 | 1,026,000,000 | 1,208,800,000 | 429,600,000 | -1,075,400,000 | 214,000,000 | 454,000,000 | ||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at beginning of year | 0 | 0 | 0 | 6,515,000,000 | 0 | 0 | 0 | 8,524,000,000 | 0 | 0 | 0 | 7,441,000,000 | 0 | 0 | 0 | 15,621,000,000 | 0 | 0 | 0 | 13,451,000,000 | 0 | 0 | 0 | 13,531,000,000 | 0 | 0 | 0 | 10,900,000,000 | -400,000 | 0 | 0 | 9,311,400,000 | ||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents at end of period | 115,000,000 | -3,922,000,000 | 11,708,000,000 | 1,299,000,000 | -3,108,000,000 | 9,716,000,000 | 626,000,000 | -1,058,000,000 | 7,980,000,000 | 1,627,000,000 | -6,085,000,000 | 15,828,000,000 | -1,000,000,000 | 2,066,000,000 | 13,024,000,000 | 608,000,000 | 2,096,000,000 | 14,656,000,000 | 1,911,000,000 | 647,000,000 | 11,695,000,000 | 1,208,800,000 | 429,600,000 | 8,236,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||
gain on divestiture of merck consumer care business | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on astrazeneca option exercise | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
loss on extinguishment of debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
divestiture of merck consumer care business, net of cash divested | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dispositions of other businesses, net of cash divested | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from astrazeneca option exercise | 0 | 0 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of idenix pharmaceuticals, inc., net of cash acquired | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition of bayer ag collaboration rights | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash inflows from net investment hedges | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other dividends paid | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dividends and distributions from equity affiliates | 5,000,000 | 3,000,000 | 4,000,000 | 5,000,000 | 4,000,000 | 3,000,000 | 7,000,000 | 59,000,000 | 66,000,000 | 59,000,000 | 110,000,000 | 63,000,000 | 5,000,000 | 110,000,000 | 59,000,000 | 56,000,000 | 66,000,000 | 30,000,000 | 65,000,000 | 56,000,000 | 65,000,000 | 60,200,000 | 81,700,000 | 104,700,000 | 77,400,000 | |||||||||||||||||||||||||||||||||||||||||||||
net decrease in cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign exchange losses related to venezuela | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on divestiture of merck consumer care | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
divestiture of consumer care business, net of cash divested | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on divestiture of certain ophthalmic products | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposition of interest in equity method investment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of interest in equity method investment | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash inflows (outflows) from net investment hedges | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on astrazeneca lp asset option exercise | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from astrazeneca lp asset option exercise | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease in restricted assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain related to merck/schering-plough partnership | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
schering-plough merger, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental cash flow information | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on astrazeneca asset option exercise | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development impairment charges | 302,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
increase in restricted assets | 200,000 | 18,100,000 | -25,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gains on distributions from astrazeneca lp | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on disposition of interest in merial limited | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from sale of interest in merial limited | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distributions from astrazeneca lp | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
decrease (increase) in restricted assets | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from the issuance of debt | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used by) provided by investing activities | -3,148,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from (used by) financing activities | 942,200,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on distribution from astrazeneca lp | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
u.s. vioxx settlement agreement charge | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
in-process research and development | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
taxes paid for internal revenue service settlement | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
distribution from astrazeneca lp | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash from (used by) investing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash used by financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accrued share-based compensation | 48,000,000 | 49,000,000 | 52,000,000 | 58,000,000 | 60,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
special, merger and acquisition-related charges and payments | -8,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
gain on sale of divested products | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
changes in assets and liabilities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
prepaid expenses and other assets | 47,000,000 | -52,000,000 | -8,000,000 | -92,000,000 | 78,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable | 88,000,000 | 154,000,000 | 37,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
other liabilities | -189,000,000 | -164,000,000 | -22,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
investing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
dispositions of property and equipment | 1,000,000 | 11,000,000 | 2,000,000 | 4,000,000 | 27,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
contributions to benefit-related trusts | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from divested products | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of short-term investments | -708,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
maturities of short-term investments | 5,000,000 | 0 | 17,000,000 | -15,000,000 | 25,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
financing activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of long-term debt | -71,000,000 | -466,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends paid to common shareholders | -106,000,000 | -105,000,000 | -106,000,000 | -106,000,000 | -105,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash dividends paid to preferred shareholders | -38,000,000 | -37,000,000 | -38,000,000 | -37,000,000 | -38,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
stock option exercises | 36,000,000 | 0 | 11,000,000 | 2,000,000 | 2,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
effect of exchange rates on cash and cash equivalents | -42,000,000 | -43,000,000 | -55,000,000 | 0 | 20,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of period | 3,373,000,000 | 0 | 0 | 2,279,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of period | 2,845,000,000 | 454,000,000 | 251,000,000 | 2,454,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease)/increase in cash and cash equivalents | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net (decrease) / increase in cash and cash equivalents | -528,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cumulative effect of a change in accounting principle, net of tax | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net income before cumulative effect of a change in accounting principle, net of tax | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
adjustments to reconcile net income before cumulative effect of change in accounting principle, net of tax to net cash provided by operating activities: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
special and acquisition-related charges and payments | 12,000,000 | 57,000,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of derivative currency options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of currency options | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from derivative instruments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquired in-process research and development | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payment to u.s. taxing authorities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
foreign currency transaction exchange loss | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
acquisition, net of cash acquired | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from preferred stock issuance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
proceeds from common stock issuance | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(payments)/issuance of long-term debt, net of issuance costs in 2007 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments of short-term borrowings | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, beginning of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash and cash equivalents, end of year | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
supplemental disclosure: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for interest, net of amounts capitalized | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
cash paid for income taxes | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchases of derivative instruments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
change in fair value of foreign currency option | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
payments to u.s. taxing authorities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used for)/provided by investing activities | 85,000,000 | -206,000,000 | -123,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
issuance of long-term debt | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash (used for)/provided by financing activities | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
purchase of derivative currency option | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
accounts payable and other liabilities | -322,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net cash provided by/(used for) operating activities | 462,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
net increase/(decrease) in cash and cash equivalents | 175,000,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
special and acquisition related charges and payments | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
short-term borrowings |